Development and Plasticity of murine plasmacytoid dendritic cells by Schlitzer, Andreas Bernhard & Bauer, Stefan (Prof. Dr.)
 Aus dem Institut für Immunologie des Fachbereichs Medizin 
der Philipps-Universität Marburg 
 
Institutsleiter:  
Prof. Dr. Stefan Bauer 
 
In Zusammenarbeit mit PD Dr. med. Anne Krug,  
Klinikum rechts der Isar, Technische Universität München 
 
 
 
Development and plasticity of murine 
plasmacytoid dendritic cells 
 
 
Inaugural-Dissertation zur Erlangung  
des Doktorgrades der Naturwissenschaften 
 dem Fachbereich Medizin der Philipps-Universität Marburg 
vorgelegt von 
 
 
 
Andreas Bernhard Schlitzer aus Fulda 
Marburg, 2012 
 Angenommen vom Fachbereich Medizin der Philipps-Universität 
Marburg am: 06.02.2012 
 
Gedruckt mit Genehmigung des Fachbereichs. 
 
Dekan: Prof. Dr. Matthias Rothmund 
 
Referent: Prof. Dr. Stefan Bauer 
 
1. Korreferent: Prof. Dr. Ulrich Steinhoff 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Table of contents 
Table of contents ............................................................................................... 1 
Index of figures .................................................................................................. 5 
List of Abbreviations ......................................................................................... 7 
1. Introduction .................................................................................................. 10 
1.1 Dendritic cells – linking innate and adaptive immunity ......................... 10 
1.1.1 Subsets of dendritic cells ........................................................................ 10 
1.1.1.1 Conventional dendritic cells ............................................................ 11 
1.1.1.2 Plasmacytoid dendritic cells ........................................................... 15 
1.1.2 Dendritic cell development ..................................................................... 19 
1.1.2.1 Conventional dendritic cell development ........................................ 19 
1.1.2.2 Plasmacytoid dendritic cell development ....................................... 23 
2. Aims of the study ........................................................................................ 26 
3. Material & Methods ...................................................................................... 27 
3.1 Published results, Schlitzer et al., Blood, 2011 .................................... 27 
3.2 Material and methods (unpublished results) ........................................ 27 
3.2.3 Material .................................................................................................. 27 
3.2.3.1 Antibodies & Cell dyes ........................................................................ 27 
Antibodies ................................................................................................... 27 
Cell Dyes .................................................................................................... 28 
3.2.3.2 Cell culture solutions, media, buffers .................................................. 28 
Media .......................................................................................................... 28 
Cell culture solutions .................................................................................. 29 
Buffers ........................................................................................................ 29 
2 
3.2.3.3 Cell lines .............................................................................................. 30 
3.3.3.4 Mice ..................................................................................................... 30 
3.3.3.5 Equipment ........................................................................................... 30 
3.2.4 Methods ................................................................................................. 31 
3.2.4.1 Cell culture of B16 FLT3L secreting melanoma .................................. 31 
3.2.4.2 Expansion of DCs by treatment with FLT3L secreting B16 melanoma
 ................................................................................................................ 31 
3.2.4.3 Isolation of murine BM ......................................................................... 31 
3.2.4.4 FACS sorting of PDC subsets for adoptive transfer ............................ 32 
3.2.4.5 Labelling of cells with Violet trace ....................................................... 32 
3.2.4.6 Adoptive transfer of pDC subsets ........................................................ 33 
3.2.4.7 Isolation of cells from lymphoid tissues of mice .................................. 33 
3.2.4.8 Isolation of murine leucocytes from the lung ....................................... 33 
3.2.4.9 Isolation of murine leucocytes from the liver ....................................... 34 
3.2.4.10 Isolation of murine leucocytes from blood ......................................... 34 
3.2.4.11 Isolation of murine leucocytes from the colon and the small intestine
 ................................................................................................................ 34 
3.2.4.12 FACS analysis of adoptively transferred pDC subsets ...................... 35 
3.2.3.13 Assessment of proliferation using dilution of Violet trace cell dye ..... 36 
3.2.3.14 Statistical analysis of results ............................................................. 36 
4. Results .......................................................................................................... 37 
4.1 Summary of results published in Blood by Schlitzer et al., 2011 ....... 37 
4.1.1 CCR9- MHC class IIlow pDCs are immediate precursors of CCR9+ MHC 
class IIint pDCs ........................................................................................ 37 
4.1.2 CCR9- MHC class IIlow pDC retain plasticity to acquire phenotype and 
function of CD11b+ MHC class IIhigh cDC-like cells ................................. 39 
4.1.3 Diversion of CCR9- MHC class IIlow pDCs from the pDC lineage is 
induced by GM-CSF ............................................................................... 40 
4.1.4 Diversion of CCR9- MHC class IIlow pDCs from the pDC lineage is 
marked by a profound change in the expression of transcription factors 41 
4.1.5 Author contributions ............................................................................... 42 
3 
4.2 Unpublished results ................................................................................ 43 
4.2.1 CCR9- and CCR9+ pDCs from the BM maintain pDC phenotype 
characteristics after in vivo expansion by FLT3L .................................... 43 
4.2.2 CCR9- and CCR9+ pDCs are equally expanded by treatment with FLT3L
 ................................................................................................................ 45 
4.2.3 CCR9- pDCs are present in all major lymphoid and non-lymphoid organs
 ................................................................................................................ 46 
4.2.4 CCR9- and CCR9+ pDCs display a similar chemokine receptor 
expression pattern .................................................................................. 47 
4.2.5 Rapid accumulation of CCR9+ and CCR9- pDCs in lymphoid organs after 
adoptive transfer in steady state mice .................................................... 49 
4.2.6 CCR9- and CCR9+ pDCs accumulate in all major lymphoid and non-
lymphoid organs upon adoptive transfer ................................................. 50 
4.2.7 CCR9- but not CCR9+ pDCs downregulate pDC-specific surface 
molecules in lymphoid and non-lymphoid organs ................................... 53 
4.2.8 CCR9- pDCs give rise to CCR9+ pDCs and to CD11b+ MHC class IIhigh 
cDCs locally in the tissues ...................................................................... 55 
4.2.9 CX3CR1 is not required for CCR9+ or CCR9- pDC recruitment to the BM 
or peripheral lymphoid organs upon adoptive transfer ............................ 58 
4.2.10 A role for GM-CSF in the tissue specific migration of CCR9- and CCR9+ 
pDCs ....................................................................................................... 60 
4.2.11 CSF2rβ signalling controls proliferation of CCR9- and CCR9+ pDCs ... 62 
4.2.12 Lack of CSF2rβ on CCR9- or CCR9+ pDCs does not impair the 
plasticity of CCR9- pDCs ......................................................................... 64 
5. Discussion ................................................................................................... 66 
5.1 CCR9- pDCs are part of the pDC lineage .................................................. 67 
5.2 Plasticity of CCR9- pDCs ........................................................................... 68 
5.3 GM-CSF, a novel factor involved in pDC homing and proliferation ........... 72 
5.4 The origin of CCR9- pDCs ......................................................................... 74 
5.5 A new model for DC development ............................................................. 75 
4 
6. Summary ...................................................................................................... 76 
7. Zusammenfassung ...................................................................................... 78 
8. References ................................................................................................... 80 
9. Acknowledgements ..................................................................................... 93 
10. Verzeichnis der akademischen Lehrer .................................................... 94 
11. Appendix .................................................................................................... 95 
11.1 Schlitzer et al., Blood, 2011 .................................................................. 95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 
Index of figures 
Figure 1 Subsets of mouse DCs found in lymphoid as well as non-lymphoid 
organs. ....................................................................................................... 11 
 
Figure 2 Schematic depiction of DC development in the BM as well as in 
peripheral tissues. ...................................................................................... 20 
 
Figure 3 Table of critical DC development related transcription factors ........... 24 
 
Figure 4 Sorting strategy for CCR9+ and CCR9- pDCs from BM. ..................... 32 
 
Figure 5 CCR9- pDC show pDC surface marker expression, but immature 
differentiation and maturation status compared to CCR9+ pDCs ............... 44 
 
Figure 6 Exposure to FLT3L expands both the CCR9- and CCR9+ pDC 
populations equally ..................................................................................... 45 
 
Figure 7 CCR9- pDCs are present in all major lymphoid and non-lymphoid 
organs ........................................................................................................ 46 
 
Figure 8 Analysis of chemokine receptor expression on CCR9- and CCR9+ 
pDCs in BM, spleen and blood of WT mice ................................................ 49 
 
Figure 10 Recovery of adoptively transferred CCR9- and CCR9+ pDCs 48h 
after transfer in lymphoid and non-lymphoid organs .................................. 51 
 
Figure 11 Percentage of BST2+ CD11c+ violet trace+ PI- cells in lymphoid and 
non-lymphoid organs 48h after adoptive transfer of CCR9- or CCR9+ pDCs
 ................................................................................................................... 53 
 
Figure 12 Phenotype of adoptively transferred CCR9- pDCs 48h after transfer ... 
 ................................................................................................................... 55 
 
Figure 13 CCR9- pDC originated pDCs and cDCs share surface characteristics 
with the endogenous pDC and cDC pool ................................................... 56 
6 
Figure 14 Recovery of transferred CCR9+ and CCR9- WT or CX3CR1 KO 
pDCs 48h after adoptive transfer to WT recipients .................................... 59 
 
Figure 15 Recovery of WT and CSF2rβ deficient CCR9+ and CCR9- pDCs into 
WT steady state recipients ......................................................................... 60 
 
Figure 16 Proliferation of WT or CSF2rβ deficient CCR9- or CCR9+ pDCs in 
BM, SP, LN and PP 48h after adoptive transfer ......................................... 62 
 
Figure 17 Percentage of BST2+ CD11c+ Violet trace+ PI- cells in BM, SPL, LN 
and PP 48h after adoptive transfer of CSF2rβ KO CCR9- or CCR9+ pDCs
 ................................................................................................................... 65 
 
Figure 18 New model for DC development in the BM as well as in peripheral 
lymphoid and non-lymphoid organs. .......................................................... 73 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 
List of Abbreviations 
BATF3 Basic leucine zipper transcriptional 
factor ATF-like 3 
BST2 Bone marrow stromal cell antigen 2 
CCL Chemokine (C-C motif) ligand 
CCR Chemokine (C-C motif) receptor 
CD Cluster of differentiation 
cDC Conventional dendritic cell 
CDP Common dendritic cell progenitor 
CpG CpG containing oligonucleotide 
CXCR Chemokine (C-X-C motif) receptor 
DC Dendritic cell 
DNA Deoxyribonucleic acid 
E2-2 E-protein 2-2 
EAE Experimental autoimmune 
encephalomyelitis 
EpCAM Epithelial cell adhesion molecule 
FLT3 FMS-like tyrosine kinase 3 
FLT3-L FMS-like tyrosine kinase 3 ligand 
Foxp Forkhead box protein 
Gfi Growth factor independent 1 
GM-CSF Granulocyte macrophage colony 
stimulating factor 
GM-CSF 
 
Granulocyte macrophage stimulating 
factor 
GR-1 
 
Ly6g; Lymphocyte antigen 6 complex, 
locus G 
ID2 DNA-binding protein inhibitor 2 
IEC-SN Intestinal epithelial supernatant 
IFN Interferon 
Ig Immunoglobulin 
IL Interleukin 
8 
IRF Interferon regulatory factor 
ITGAX Integrin alpha X 
LCMV Lymphocytic choriomeningitis virus 
Lin Lineage 
LPS Lipopolysaccharide 
Ly Lectin-type killer cell inhibitory receptor 
M-CSF Macrophage colony stimulating factor 
M-CSF-R Macrophage colony stimulating factor 
receptor 
MDP Macrophage dendritic cell progenitor 
MHC Major histocompatibility complex 
mTOR Mammalian target of rapamycin 
MyD88 
 
Myeloid differentiation primary 
response gene 88 
NFkb Nuclear factor kappa-light-chain-
enhancer of activated B cells 
pDC Plasmacytoid dendritic cell 
Pre-cDC Pre conventional dendritic cell 
PU.1 spleen focus forming virus proviral 
integration oncogene spi1 
RelB Relb avian reticuloendotheliosis viral 
(v-rel) oncogene related B 
RIG Retinoic acid inducible gene 
RLR RIG-1 like receptor 
RNA Ribonucleic acid 
Sca-1 Stem cell antigen 1 
Siglec H Sialic acid binding Ig-like lectin H 
SLE Systemic lupus erythematodes 
SPL 
BM 
LN 
PP 
SI 
Spleen 
Bone marrow 
Lymph node 
Peyer’s patch 
Small intestine 
9 
CSF2r 
Pre-pDC 
LI 
LG 
Colony stimulating factor 2 receptor  
Pre plasmacytoid dendritic cell 
Liver 
Lung 
STAT Signal transducers and activators of 
transcription protein 
TCF4 Transcription factor 4 
TGF Transforming growth factor 
Th T helper cell type 
TLR Toll like receptor 
TNF Tumour necrosis factor 
XBP-1 X-box binding protein 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 
1. Introduction 
The immune system has evolved to defend the body from various threats such 
as bacterial, viral, fungal and parasitic infection while preventing the induction of 
autoimmunity. This defense system is split into two very different but closely 
interconnected branches - the innate and the adaptive immune system. 
Interaction between innate and adaptive immunity is necessary to provide 
optimal defense against various pathogens. One of the most important 
connecting parts in this system are dendritic cells (DC), which I will focus on in 
the following chapters of this introduction. 
1.1 Dendritic cells – linking innate and adaptive 
immunity 
1.1.1 Subsets of dendritic cells 
Intensive research identified two broad categories of DCs, conventional DCs 
(cDCs) and plasmacytoid DCs (pDCs), which can be distinguished by their 
morphology and the expression of certain unique surface molecules. In addition, 
they differ in their capacities to produce cytokines and induce T cell activation in 
response to various stimuli. Depending on the subset and activation state, DCs 
are able to shape different kinds of immune responses such as cytotoxic T cell 
responses and T-helper cell type 1 (Th1, IFN-γ-producing), Th2 (IL-4 producing) 
and Th17 (IL-17 producing). Differences in their capacity to capture and process 
antigen and to present this antigen to T cells, to co-stimulate T cells and to 
secrete various combinations of cytokines and chemokines, lead to different 
types of effector T cell responses.  
 
These two categories of DCs, will be described below in detail. Because this 
study was conducted in mice, this introduction will be limited to recent work 
done in the mouse experimental system, however similar or equivalent 
populations in humans do exist and largely have similar functions. 
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1.1.1.1 Conventional dendritic cells 
CDCs can be found in every organ in mice and can be identified by their 
specific DC morphology and with the help of certain uniquely expressed surface 
molecules. In mice, cDCs in lymphoid and non-lymphoid organs such as the 
spleen or the lung express high levels of the integrin CD11c and high levels of 
major histocompatibility complex (MHC) class II (Figure 1) (Steinman and 
Figure 1 Subsets of mouse DCs found in lymphoid as well as non-lymphoid organs. 
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Inaba, 1999). Another feature of cDCs is the ability to mature in response to 
microbial stimuli which integrate into various pathogen recognition receptor 
pathways such as the toll like receptor (TLR) family pathway and the 
intracellular RNA receptors of the RIG-I like receptor family pathway. Maturation 
after stimulation of the TLR pathway is dependent on the intracellular signalling 
adaptors MyD88 (TLRs 1,2,4,5,6,7,8,9) and Trif (TLRs 3 & 4) and leads to the 
induction of pro-inflammatory cytokines and to upregulation of cell surface 
molecules such as CD69, CD80, CD86 and CD40, which are crucial for efficient 
T cell co-stimulation (Barchet et al., 2005). 
 
In lymphoid organs three types of CD11chigh MHC class IIhigh cDCs can be 
distinguished, CD4+ CD11b+ DCs, CD4- CD8α- CD11b+ DCs and CD8α+ 
CD11b- DCs (Figure 1) (Shortman and Liu, 2002). CD8α- CD11b+ DCs make up 
for approximately 70 % of all DCs in the spleen. They express high levels of the 
TLRs 1-9 and also the cytosolic RNA receptor RIG-I. Upon stimulation with 
various TLR ligands CD8α- CD11b+ DCs are able to produce high amounts of 
IL-6 but only low levels of IL-12p70, which skews the T cell response induced 
by these cells towards the Th2 response (Moser and Murphy, 2000). CD8α+ 
CD11b- DCs, account for 20 % of DCs in lymphoid organs, such as the spleen 
and lymph nodes and 70 % of DCs in the thymus. CD8α+ DCs express all TLRs 
except TLR7 and do not express the intracellular RNA receptor RIG-I either 
(Delamarre and Mellman, 2011). In the presence of TLR ligands such as 
immune stimulatory CpG DNA or lipopolysaccharide (LPS) CD8α+ DCs produce 
high levels of IL12p70 (Hochrein et al., 2001), which promotes the induction of 
Th1 immunity (Hildner et al., 2008). Most importantly CD8α+ DCs are able to 
efficiently cross-present soluble or cell-bound antigen on MHC class I to induce 
strong CD8+ T cell immunity against tumours and viruses whereas CD8α- DCs 
fail to do so (Hildner et al., 2008). Interestingly, under steady state conditions 
CD8α+ DCs, which can be found in lymphoid organs and the spleen, are able to 
process antigen delivered via the cell surface receptor DEC 205 and induce 
antigen specific Foxp3+ regulatory CD4+ T cells in the spleen and in the lymph 
nodes due to their ability to produce transforming growth factor β (TGF-
β) (Yamazaki et al., 2008). This suggests that CD8α+ DCs in the steady state 
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may play a role in the induction and maintenance of peripheral tolerance to self-
antigens. 
 
Subsequently several elegant studies addressed the phenotype and function of 
cDCs in non-lymphoid organs such as lung, liver and small intestine (Bogunovic 
et al., 2009; Plantinga et al., 2010; Steinman and Cohn, 1973; Varol et al., 
2009). Similar to what was found in lymphoid organs, cDCs in lung, liver and the 
intestine can be divided into two main populations with distinct phenotypes and 
functions. In the lamina propria of the small intestine and the colon two subsets 
of cDCs can be divided by the expression of the chemokine receptor CX3CR1 
and of the integrin CD103 (Cepek et al., 1994; Jung et al., 2000). Both 
populations of DCs show a similar DC like morphology and localize in the 
lamina propria but have distinct functional properties. CX3CR1+ CD103- DCs 
sample luminal antigens by projecting dendrites into the gut lumen. This 
process is dependent on the receptor for fractalkine CX3CR1 as it is absent in 
CX3CR1 KO animals (Niess et al., 2005). However, the exact function and 
mechanism of this is not yet fully understood. Additionally, CX3CR1+ CD103- 
DCs were shown to produce high amounts of Tumour-necrosis-factor-α (TNF-α) 
in conditions of intestinal inflammation (Niess and Adler, 2010; Varol et al., 
2009). On the other hand CX3CR1- CD103+ DCs where shown to be able to 
capture antigen in the lamina propria and transport this antigen efficiently to the 
mesenteric lymph node (Macpherson and Uhr, 2004; Schulz et al., 2009). In the 
mesenteric lymph node under steady state conditions CX3CR1- CD103+ DCs 
are able to induce Foxp3+ CD4+ T cells in a TGF-β and retinoic acid dependent 
manner (Coombes et al., 2007; Sun et al., 2007). This process is thought to be 
involved in tolerance to food antigens as well as to antigens of the commensal 
bacterial flora in the gut (Rescigno et al., 2001). Interestingly, in the event of 
infection or activation of CD103+ DCs, these DCs can induce T cell homing to 
the intestine and the mesenteric lymph node as well as an overall Th17 type 
immune response (Laffont et al., 2010; Lewis et al., 2011). Additionally a third 
subset of DCs can be found exclusively in the gut, which can be identified by 
the co-expression of CD11b and CD103. These cells do not express CX3CR1 
similar to CD103+ DCs. Functionally, CD11b+ CD103+ DCs migrate in a CCR7 
14 
dependent manner to the mesenteric lymph node and are able to prime naïve T 
cells as efficient as CD103+ DCs. 
 
In the lung, DCs are found as a dense network of cells distributed basolaterally 
to the epithelial layer as well as in the alveolar space. Two different subsets of 
cDCs can be found in steady state lungs of mice, CD11b+ CX3CR1+ DCs and 
CD103+ langerin+ DCs. CD11b+ CX3CR1+ DCs are located directly under the 
airway epithelium and do not invade the alveolar space in the steady state 
(Wikstrom and Stumbles, 2007). CD11b+ cDCs produce a wide array of 
inflammatory mediators and chemokines, such as IL-6, CCL22 and CCL17, 
which attract and activate T cells (van Rijt et al., 2005). However it is not clear 
what their exact contribution to T cell immunity and to the induction of allergic 
reactions in the lung is. CD103+ DCs in the lung reside close to the alveolar 
epithelium and are able to sample antigens by attaching their dendrites to tight 
junction proteins of the airway epithelium and thereby accessing the lumen 
(Jahnsen et al., 2006). Similar to CD103+ DCs found in the gut, these cells 
migrate to the draining lymph nodes after antigen encounter (GeurtsvanKessel 
and Lambrecht, 2008; GeurtsvanKessel et al., 2008). Interestingly, in contrast to 
CD103+ DCs in the gut, lung CD103+ DCs are prone to induce Th2 cells rather 
than regulatory T cells or Th17 cells (Lambrecht and Hammad, 2009). 
Furthermore careful analyses by Sung et al. revealed that CD103+ DCs occur at 
a much higher frequency in the lung as compared to other non-lymphoid organs 
such as the intestine (Sung et al., 2006). 
 
In the skin, the body’s largest organ, cDCs play a crucial role in patrolling and 
controlling this border to the outside world. Therefore cDCs and Langerhans 
cells form a dense network of cells, which are distributed in the dermis as well 
as in the epidermis (Merad et al., 2008). In the dermis cDCs can be separated 
by their expression of langerin. Langerin+ DC also express the marker CD103 
but lack CD11b. Langerin- DCs on the other hand are CD11b+ and do not 
express CD103 (Ginhoux et al., 2009). Both cell types are negative for epithelial 
cell adhesion molecule (EpCAM) in contrast to Langerhans cells, which also 
reside in the dermis. Langerhans cells, present as migratory Langerhans cells in 
the dermis on their way to the lymph node, express high levels of langerin, 
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CD11b and EpCAM, but lack expression of CD103. This separate antigen 
presenting cell type can also be found in the epidermis, directly under the first 
layer of keratinocytes. At this location, Langerhans cells are thought to sample 
antigens, and are able to elicit immune responses (Helft et al., 2010). Also 
Langerhans cells of the epidermis and the dermis are resistant to radiation in 
contrast to other DC subsets found throughout the body, which suggests that 
Langerhans cells are long-lived and are not proliferating in the steady state 
(Ginhoux et al., 2007). Both DC subsets, CD11b+ CD103- and CD11b- CD103+ 
DCs, however are sensitive to radiation, which leads to the conclusion that 
these cells are actively proliferating in the steady state (Ginhoux et al., 2009). 
 
In conclusion cDCs form a diverse network of highly specialized cells, which is 
distributed throughout the body and is able to react to pathogens through 
subset specialization and utilization of differentially expressed receptors, to 
mount appropriate tolerogenic or immunogenic immune responses. 
1.1.1.2 Plasmacytoid dendritic cells 
PDCs are characterized by their unique plasma cell like morphology and by the 
expression of intermediate levels of the integrin CD11c, low levels of CD11b 
and expression of the B220 and Ly6C/G. Furthermore pDCs express the pDC 
specific surface molecules sialic acid binding Ig-like lectin H (Siglec H) and 
bone marrow stromal cell antigen 2 (BST2) (Figure 1) (Blasius et al., 2006a; 
Blasius et al., 2006b; Zhang et al., 2006). PDCs can be found in all lymphoid 
organs. Additionally they can also be found in most non-lymphoid organs, 
however in substantially lower quantities compared to cDCs. The vast majority 
of pDCs can be found in the bone marrow (BM). Approximately 3 % of all BM 
hematopoietic cells can be identified as pDCs by their expression of Siglec H 
and BST2. Additional markers used for pDC identification albeit less specific 
ones are the B cell marker B220, Ly6c and Ly49q (Kamogawa-Schifter et al., 
2005; Toma-Hirano et al., 2007). The pDC population can be further divided into 
CCR9+ and CCR9- pDCs (Schlitzer et al., 2011; Wendland et al., 2007). Both 
populations express CD9 as long as they reside in the BM and downregulate 
expression of CD9 upon entry into lymphoid organs (Bjorck et al., 2011). 
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Additionally pDCs express other surface markers in varying or low degrees 
such as CD8α(+/-), CD4(+/-) and CD11blow (Asselin-Paturel et al., 2001). 
Interestingly, in the steady state pDCs display only low amounts of MHC class II 
on their surface and costimulatory molecules, like CD80 and CD86 are almost 
absent without appropriate stimulation.  
 
PDCs can also be found in various lymphoid tissues such as the spleen, thymus 
and lymph nodes. PDCs found in these lymphoid organs are phenotypically 
similar to those found in the BM however lack the expression of CD9 (Bjorck et 
al., 2011). Furthermore CCR9- pDCs, which constitute up to 30 % of the pDC 
population in the BM, rarely exceed 10 % of the total pDC population in the 
peripheral lymphoid organs as shown in this dissertation (Schlitzer et al., 2011). 
PDCs are thought to migrate to the lymphoid organs via the blood stream 
entering via high endothelial venules. They then migrate to the T cell areas of 
the lymph node in a CCR7 dependent manner (Seth et al., 2011). In contrast, 
cDCs enter the lymphoid organs via afferent lymphatics. 
 
PDCs were first characterized by their ability to produce excess quantities of 
type I IFN in response to viral infections (Asselin-Paturel et al., 2001; Nakano et 
al., 2001). Subsequently it was shown that pDCs are the major type I interferon 
producing cell type in mice and man. They utilize a specific set of innate 
immune receptors to sense viral and bacterial infection (Cella et al., 1999). 
PDCs express high levels of TLR7 and 9. In response to TLR7 and 9 ligands, 
single stranded RNA and CpG DNA respectively, pDCs produce high levels of 
interferon-α (IFN-α). The ability to rapidly produce and secrete high amounts of 
IFN-α is due to the high expression of x-box binding protein 1 (XBP-1), a master 
regulatory protein of the secretory pathway and to the high constitutive 
expression of interferon regulatory factor (IRF) 7 in unstimulated pDCs 
(Iwakoshi et al., 2007; Izaguirre et al., 2003; Kerkmann et al., 2003). 
Interestingly, rapid production of IFN-α is independent of the IFN-α/β receptor 
mediated feedback loop upon viral infection, but necessary for IFN-α production 
upon encounter with non-replicating virus (Blasius et al., 2010; Kerkmann et al., 
2003; Kumagai et al., 2009). Stimulation of pDCs with TLR7 or 9 ligands not 
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only induces IFN-α but also leads to the secretion of TNF-α, IL-12 and IL-6. 
Additionally upon stimulation pDCs are able to present antigens and prime T 
cells. They also attract other types of immune cells, such as plasma cells and 
NK cells (Krug et al., 2003; Liu et al., 2008; Sapoznikov et al., 2007). PDCs, in 
contrast to cDCs are characterized by a low turnover and are therefore long-
lived cells in contrast to cDCs (Liu et al., 2007). Furthermore several studies 
revealed that pDCs are able to undergo a phenotypical and functional switch 
towards cDCs under the influence of a lymphocytic choriomeningitis virus 
(LCMV) infection (Zuniga et al., 2008; Zuniga et al., 2004). In addition to their 
function as sentinels and rapid producers of type I interferons pDCs are also 
able to instruct adaptive immunity. Le Bon et al. and others were able to show 
that type I interferon by pDCs is needed to instruct B cells to develop into 
antibody producing plasma cells and to do class switching from IgG to IgM (Le 
Bon et al., 2001; Poeck et al., 2004). Additionally to inducing T cell proliferation 
upon activation (Cella et al., 2000), pDCs are also able to produce T cell 
attracting chemokines upon activation, such as CCL3 and CCL4, which attract 
CD4+ as well as CD8+ T cells to sites of infection (Krug et al., 2002; Penna et 
al., 2002) as well as to the T cell areas of lymph nodes. 
 
Despite their role in the induction of immunity, pDCs of lymphoid organ origin 
have also been implicated in the induction of tolerance in certain experimental 
models. In a model of acute allogeneic graft versus host disease CCR9+ pDCs 
were able to induce Foxp3+ T cells upon adoptive transfer and suppressed 
disease. However, the exact mechanism of this regulatory T cell induction is not 
well understood (Hadeiba et al., 2008). Also targeting of myelin oligodendrocyte 
glycoprotein (MOG) peptide to pDCs via Siglec H leads to belated onset of 
experimental autoimmune encephalomyelitis (EAE) (Loschko et al., 2011). 
These findings further strengthen the immunoregulatory role of pDCs. 
Furthermore Irla et al. showed that selective ablation of MHC class II on pDCs 
leads to exacerbated course of EAE (Irla et al., 2010). However pDCs have also 
been implicated in the break of tolerance in certain models of autoimmunity, 
which are associated with type I IFN, such as systemic lupus erythematodes 
(SLE) and psoriasis (Blomberg et al., 2001; Nestle et al., 2005). Several studies 
showed that IFN-α/β production by pDCs triggered by RNA or DNA immune-
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complexes in the absence of infection can lead to a break of peripheral 
tolerance and to the induction of SLE or psoriasis (Gregorio et al., 2010; Lande 
et al., 2011; Lande et al., 2007; Savarese et al., 2006). Also in the EAE model, 
as shown by Isaksson et al., pDCs can contribute to the pathogenesis of EAE 
via their ability to produce IFN-α, which was necessary for exacerbated disease 
in the early course of the disease (Isaksson et al., 2009). 
 
PDCs can also be found in lung, liver and skin as well as the small intestine and 
the colon. In these non-lymphoid organs the phenotype of pDCs is similar to the 
phenotype of pDCs, which can be found in spleen and lymph nodes. In the lung 
pDCs can be found in the lamina propria directly under the bronchial epithelium 
(Hammad and Lambrecht, 2011). De Heer et al. demonstrated that these pDCs 
are able to confer tolerance to inhaled antigen in the steady state to prevent the 
induction of asthma. Depletion of pDCs, before inhalation of otherwise non 
asthma inducing antigen, leads to the production of IgE, Th2 cytokines, airway 
eosinophilia and goblet cell hyperplasia and the establishment of asthma, 
showing that pDCs are necessary to sustain tolerance in this model (de Heer et 
al., 2004). In addition, Goubier et al. were able to show that depletion of pDCs 
led to the abrogation of tolerance to oral antigen. This was attributed to the loss 
of pDCs in the liver (Goubier et al., 2008). 
 
Taken together pDCs have a diverse role in the induction and maintenance of 
immunity to various kinds of pathogens and in the induction of tolerance to self 
as well as foreign antigens. 
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1.1.2 Dendritic cell development 
DC development is a tightly regulated multi-step process, which is able to give 
rise to several different populations and subsets of DC in the BM, lymphoid 
organs and non-lymphoid organs. This process of generating different DC types 
and subsets from hematopoietic precursors will be outlined in the following 
chapters. 
1.1.2.1 Conventional dendritic cell development 
Hematopoietic stem cells in the BM, which are characterized by expression of 
CD34 and lack of expression of lineage markers such as CD4, CD8, CD3ε, 
B220, CD19, CD11b, Gr-1, NK1.1 and TER-119 (termed Lin-), progressively 
mature to a stage were commitment to either the myeloid or lymphoid lineage 
occurs (Karsunky et al., 2003). At this stage the common myeloid and common 
lymphoid precursor cells arise. Lymphoid precursors can give rise to T and B 
cells as well as NK cells, myeloid precursors on the other hand are restricted to 
differentiate into the myeloid lineage (Akashi et al., 1999). Runx 1, a 
transcription factor involved in hematopoietic stem cell development, was 
shown to be important for this transition (Dominguez-Soto et al., 2005). In a 
next step, myeloid progenitors differentiate into FLT3+ Lin- CD117high (c-kit), 
CX3CR1+ CD115+ (M-CSFR) monocyte/macrophage DC progenitors (MDP) in 
the BM, which are able to give rise to Ly6c+/- monocytes, certain subsets of 
macrophages and the common DC progenitor (CDP, Geissmann et al., 2010). 
Transition of the MDP towards the DC lineage is mediated by FMS-like tyrosine 
kinase 3 ligand (FLT3L), which acts on a subset of MDPs which expresses 
FMS-like tyrosine kinase 3 (FLT3) but are still negative for lineage markers 
(Waskow et al., 2008). MDPs develop into CDPs or pro-DCs under the 
influence of FLT3L (Onai et al., 2007). CDP development is critically dependent 
on FLT3L as well as M-CSFR as it is severely reduced in FLT3L and 
macrophage colony stimulating factor (M-CSF) receptor KO animals. 
Furthermore it was shown by Onai et al. that CDPs are able to differentiate into 
pure CD11c+ MHC class II+ DCs upon culture with FLT3L or granulocyte 
macrophage colony stimulating factor (GM-CSF), further demonstrating the 
importance of these two growth factors (Onai et al., 2007). The appropriate 
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receptor repertoire needed to respond to these growth factors is controlled by 
the master regulator of GM-CSF and FLT3L receptor expression, spleen focus 
forming virus proviral integration oncogene spi1 (PU.1) (Carotta et al., 2010). 
PU.1 is able to directly regulate the expression levels of these receptors and is 
therefore crucial for the response to FLT3L and GM-CSF. 
 
Figure 2 Schematic depiction of DC development in the BM as well as in peripheral 
tissues. 
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CDPs are committed to DC development, including the generation of cDCs and 
pDCs. CDPs, which are CD11c- MHC class II- then successively develop into 
CD11c+ MHC class II- Pre-DCs. Pre-DCs as defined by Naik et al. (Naik et al., 
2007) are still able to differentiate into cDCs and pDCs (Naik et al., 2007). 
Commitment to either cDC or pDC populations occurs early in the proliferation 
cycle of these precursors, meaning they contain single precursors which are 
restricted to produce pDCs or cDCs or both. Definite cDC development starts 
with the cDC committed DC precursor (pre-cDC) and is governed by the growth 
factors FLT3L, GM-CSF and M-CSF (Figure 2) (Fancke et al., 2008; Kingston et 
al., 2009; Onai et al., 2007; Waskow et al., 2008). Liu et al. set out to study the 
development and homeostasis of cDCs in peripheral lymphoid organs. Adoptive 
transfer experiments revealed that CDPs develop in the BM, into pre-cDCs 
which upregulate the integrin CD11c and are MHC class II- and FLT3+ (Liu et 
al., 2009; Liu et al., 2007). These Pre-cDCs are now restricted to give rise to 
cDCs, rather than to pDCs or monocytes. Pre-cDCs are able to leave the BM 
and migrate through the blood stream (0.03 % of blood lymphocytes) to 
peripheral lymphoid organs (Liu et al., 2009). They are able to enter the 
lymphoid organs through high endothelial venules. Once in peripheral lymphoid 
organs pre-cDCs undergo multiple cell divisions, under the regulation of local 
FLT3L levels and differentiate into various subsets of cDCs, such as CD8α+ and 
CD11b+ cDCs present in the peripheral lymphoid organs (Figure 2, (Liu et al., 
2009; Liu et al., 2007).  
 
However final development of cDCs subpopulations depends on different 
transcription factors. PU.1, signal transducers and activators of transcription 
protein 3 (STAT3), transducers and activators of transcription protein 5 (STAT5) 
and Ikaros are equally necessary for the development of both cell populations 
from the pre-cDC precursor (Figure 3, (Dakic et al., 2005; Laouar et al., 2003; 
Wu et al., 1997). On the other hand IRF8, DNA-binding protein inhibitor 2 (ID2) 
and basic leucine zipper transcriptional factor ATF-like 3 (BATF3) transcription 
factors are critical for CD8α+ cDC development in lymphoid organs (Figure 3) 
(Aliberti et al., 2003; Hacker et al., 2003; Hildner et al., 2008; Tsujimura et al., 
2003). Equally important for development of CD11b+ cDCs are IRF2, IRF4 and 
Relb avian reticuloendotheliosis viral oncogene related B (RelB) transcription 
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factors (Ichikawa et al., 2004; Suzuki et al., 2004; Wu et al., 1998). Loss of the 
aforementioned transcription factors leads to loss or severe reduction of one or 
both of the two cDC populations (Figure 3). 
 
CDC development in non-lymphoid organs is also dependent, at least to a 
major part, on pre-cDC precursors and to a minor extend on monocytes 
(Geissmann et al., 2010). Once pre-cDCs reach peripheral non-lymphoid 
organs like the small intestine or the lung they undergo multiple cell divisions 
and are able to produce several different DC subsets (Ginhoux et al., 2009). 
Varol et al. and Bogunovic et al. were able to show that the progeny of 
adoptively transferred CDPs and pre-cDCs in small intestine were CD103+ DCs 
and to a minor extend CX3CR1+ CD11b+ DCs (Bogunovic et al., 2009; Varol et 
al., 2009). Also adoptively transferred monocytes were not able to generate 
CD103+ DCs, but were able to produce CX3CR1+ CD11b+ progeny. These two 
processes were both critically dependent on FLT3. However for the generation 
of CD103+ DC GM-CSF receptor and GM-CSF were needed and according to 
their monocyte like ontogeny also M-CSF receptor was necessary for 
generation of CX3CR1+ CD11b+ DCs. Interestingly IRF8, ID2 and BATF3 
transcription factors, which are necessary for development of CD8α+ DCs in 
lymphoid organs, are also crucial to the development of CD103+ DCs in the 
periphery, leading to the assumption that these two cell types share a common 
developmental program (Figure 3) (Edelson et al., 2010; Ginhoux et al., 2009; 
Helft et al., 2010). 
 
Similar to what was found in the small intestine, CD103+ cDCs in the lung also 
originate from pre-cDCs. CD11b+ CD103- lung cDCs are in part of monocyte 
origin and pre-cDC origin in line with the results obtained in the small intestine 
(Ginhoux et al., 2009; Helft et al., 2010). In the skin, where langerin+ and 
langerin– DCs can be found, only langerin– cDC originate from pre-cDCs, 
whereas langerin+ so called Langerhans cells originate from a local precursor, 
which has maintained a self renewing potential within the adult skin (Chorro and 
Geissmann, 2010; Chorro et al., 2009).  
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Under inflammatory conditions induced by infection or inflammation, monocytes 
are recruited to a greater extend than in the steady state, dependent on CCR2 
and CCL2, to these sites. They also contribute substantially to the DC pool in 
non-lymphoid organs, by differentiating into inflammatory DCs, with the capacity 
to produce substantial amounts of IL-6, IL-12 and TNF-α as well as the capacity 
to capture antigen and present it to T cells (Auffray et al., 2009; Cheong et al., 
2010; Shi et al., 2011). Additionally it was shown that recruited monocytes can 
contribute to the steady state pool of CD11b+ CD103- CX3CR1+ in the intestine 
and that this is dependent on the presence of commensals (Niess and Adler, 
2010).  
1.1.2.2 Plasmacytoid dendritic cell development 
PDCs can develop from the CDP, which originates from the common myeloid 
precursor in the BM (Figure 2) (Naik et al., 2007). However, adoptive transfer 
experiments show that pDCs are not only able to originate from the common 
myeloid precursor and the CDP, but are also able to develop from the common 
lymphoid progenitor. This is supported by the notion that a fraction of pDCs in 
the BM harbours a lymphoid cell like IgH rearrangement in their DNA, hinting to 
a lymphoid origin (Shigematsu et al., 2004). However it is not clear if pDCs arise 
only locally in the BM directly from the CDP or if there are intermediate more 
pDC committed cells, which contribute to the pDC pool, similar to the pre-cDC. 
 
PDCs are critically dependent on the growth factor FLT3L, shown by the fact 
that animals, which lack FLT3L, have a strongly reduced pDC frequency in their 
BM (Gilliet et al., 2002). However, it is not entirely clear how FLT3L is 
performing its pDC committing action in pDC development. A study by 
Sathaliyawala et al. showed that in contrast to other cell types, pDCs were 
specifically sensitive to downstream signalling triggered by FLT3L via the 
mTOR complex in DCs (Sathaliyawala et al., 2010). Moreover mice that have a 
deletion in the genes encoding for IRF8, Ikaros, XBP-1 or growth factor 
independent 1 (Gfi1) show reduced or absent pDC counts in the BM and the 
periphery (Figure 3 (Iwakoshi et al., 2007; Rathinam et al., 2005; Schiavoni et 
al., 2002; Wu et al., 1997). Yet, these mutations also affect various other DC 
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subsets. E-protein 2-2 (E2-2, TCF4), a basic helix-loop-helix transcription factor, 
serves as an essential transcription factor, which is necessary and sufficient to 
induce pDC commitment in progenitors (Figure 3 Ghosh et al., 2010). 
Furthermore, it is specific for the pDC lineage, as no other DC subset is deleted 
or reduced in E2-2 KO animals. In the BM only B cells and pDC express 
detectable levels of E2-2 similar to what was shown for Spi-b (Cisse et al., 
2008). However it is unclear how the onset of pDC commitment is regulated. 
One explanation for that might be that pDC express higher levels of E2-2 
protein than B cells and cDCs and that in contrast to cDC, pDCs only express 
very low levels of ID2, which is a protein antagonist for E2-2 (Cisse et al., 2008; 
Crozat et al., 2010). In spite of this, the signals, which determine the lineage 
commitment of a progenitor to the pDC lineage and the ensuing upregulation of 
E2-2 and its target genes such as Spi-b and IRF8 is not fully understood. 
Additionally, E2-2 is able to repress the expression of genes involved in cDC 
development directly, such as ITGAX (coding for CD11c) and ID2, in contrast 
ID2 is able to inhibit E2-2 activity, showing that the ratio of ID2 and E2-2 is an 
important player in pDC commitment. This process of posttranscriptional 
regulation and direct transcriptional regulation is most likely very important for 
the commitment of precursors to the pDC lineage (Reizis, 2010; Reizis et al., 
Figure 3 Table of critical DC development related transcription factors; Red colour 
indicates crucial transcription factors for the aforementioned population. 
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2011). Interestingly, a study by Ghosh et al. showed that E2-2 expression is not 
only necessary to induce commitment to the pDC lineage, but it is also crucial 
for maintaining a pDC phenotype, because induced ablation of E2-2 in mature 
pDCs led to the acquisition of a cDC phenotype in these cells (Ghosh et al., 
2010). Along this line Bar-On et al. were able to show that alternative CD8α+ 
CX3CR1+ cDCs, resembling pDCs by gene expression profile, exist in the 
spleen, which are sensitive to E2-2 deletion and also harbour the pDC specific 
IgH rearrangement. It is therefore thought that these cells branch of from a not 
yet fully committed pDC precursor, which fails final pDC differentiation (Bar-On 
et al., 2010). 
 
Additionally, Zuniga et al. reported that under inflammatory conditions induced 
by LCMV infection mature pDCs were shown to acquire a cDC phenotype. This 
effect was critically dependent on IFN-α, elicited by the virus (Zuniga et al., 
2004). Interestingly, pDCs which were able to deviate from the pDC lineage 
lacked the expression of Siglec H, a pDC specific marker, similar to the CD11c+ 
B220+ Siglec H- BST2- cells described by Segura et al. in spleen, which were 
cDC precursors (Segura et al., 2009). In contrast to that, it was also reported 
that treatment with recombinant IFN-β or IFN-α, favoured the generation of 
pDCs instead of cDC development in FLT3L BM cultures (Watowich and Liu, 
2010). 
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2. Aims of the study 
The aim of this study was to investigate pDC lineage commitment in vitro and in 
vivo. It was believed that pDCs arise from the common dendritic cell progenitor 
(CDP) in the BM and that terminally differentiated cells leave the BM and show 
a stable phenotype in the periphery. As a consequence the pDC lineage would 
be less flexible than the cDC lineage to adapt to the requirements of specific 
tissues and situations, such as infection or inflammation. 
 
CDCs can be generated from a tissue resident precursor (pre-cDC), which is 
able to leave the BM and to develop in the tissue into different subtypes of DCs 
allowing adaptation to local requirements. It had to be tested if this hypothesis 
was also true for pDC development. Therefore it was investigated if pDC 
development and its adaptation to the local tissue environment can take place 
in peripheral lymphoid as well as non-lymphoid tissues.  
 
Several questions needed to be addressed in this context. First, the BM pDC 
population, which was believed to be a homogenous cell population had to be 
investigated for differences in the expression of cell surface markers to identify 
cell populations within the pDC population, which harbour different development 
potential and can therefore be precursors of locally derived pDC populations. 
Secondly, it had to be established that these cells were able to leave the BM 
and could be found in peripheral lymphoid and non-lymphoid organs; a 
prerequisite for further development in these tissues. Furthermore, the 
developmental potential of the different identified pDC populations had to be 
tested in vitro as well as in vivo. The aim of this was to identify cell populations 
within the pDC population, which were able to give rise to terminally 
differentiated pDCs in the tissue, thereby allowing adaptation to local 
microenvironments. Additionally, plasticity of different pDC subsets to deviate 
from the pDC lineage into the cDC lineage was assessed in vitro as well as in 
vivo. At last the question was asked, which cytokines are required for pDC or 
cDC commitment in the different tissues. 
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3. Material & Methods 
3.1 Published results, Schlitzer et al., Blood, 2011 
 
Materials and methods used in the published results are presented in the 
paper (see appendix) 
3.2 Material and methods (unpublished results) 
3.2.3 Material 
3.2.3.1 Antibodies & Cell dyes  
Antibodies 
Antigen Clone Fluorchrome Manufacturer 
BST2 120G8 FITC; APC Prepared in our 
own lab 
CCR4 2G12 PE Ebioscience 
CCR6 R6H1 PE-Cy5.5 Ebioscience 
CCR7 4B12 PE-Cy5.5 Ebioscience 
CCR9 CW1.2 PE; APC Ebioscience 
CD115 AFS98 Biotin labelled; APC Ebioscience 
CD11b M1/70 APC; APC-efluor780 Ebioscience 
CD11c N418 PE-Cy7 Ebioscience 
CD135 A2F10 Biotin labelled; PE Ebioscience 
CD4 GK1.45 APC Ebioscience 
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Cell Dyes 
 
Dye Final concentration used Manufacturer 
Violet Trace; Efluor 450 5µM Invitrogen 
 
3.2.3.2 Cell culture solutions, media, buffers 
Media 
 
Name Formulation Manufacturer 
RPMI RPMI Gibco 
 
 
 
 
 
RPMI complete RPMI Gibco 
10 % FCS 
1 % non essential AA 
1 % Glutamax 
1 % Penicillin/Streptomycin 
 
DC Medium RPMI Promocell 
10 % FCS 
CD8 53-6.7 APC Ebioscience 
CXCR3 173 PE-Cy5.5 Ebioscience 
CXCR4 2B11 PE-Cy5.5 Ebioscience 
MHC class II M5 / 114.15.2 Efluor 450; PE; APC-
Efluor780 
Ebioscience 
Sca-1 D7 PE-Cy5.5 Ebioscience 
Siglec H 440c FITC; APC Prepared in our 
own lab 
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1 % non essential AA 
1 % Glutamax 
1 % Penicillin/Streptomycin 
500 mM β-mercaptoethanol 
Cell culture solutions 
 
Name Manufacturer 
β-mercatopoethanol solution 14.2 M Sigma-aldrich 
EDTA solution 0.5 M Gibco 
Glutamax 100x PAA 
Non essential amino acids 100x PAA 
Penicillin / Streptomycin solution 100x PAA 
Sodium pyruvate solution 100 mM PAA 
Trypsin/EDTA solution PAA 
Buffers 
 
Name Formulation Manufacturer 
In vivo injection PBS PBS without Ca2+/Mg2+ PAA 
 
 
 
FACS buffer PBS without Ca2+/Mg2+ PAA 
2 % FCS 
 
 
MACS buffer / Sort buffer PBS without Ca2+/Mg2+ PAA 
2 % FCS 
2 mM EDTA 
 
Red blood cell lysis buffer 4.1 g ammoniumchlorid Prepared in our 
own lab 500 µl 1M Tris HCL 
Add sterile water up to 500 ml 
Adjust pH to 7.5 
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3.2.3.3 Cell lines 
All cell lines and primary tissue digestions were performed at 37 °C and 5 % 
CO2 in a humidified incubator 
 
B16 FLT3L melanoma cell line 
As described in Dranoff et al. (Dranoff et al., 1993) B16 melanoma cell line 
expressing FLT3L was maintained in RPMI complete at 5 % CO2, 37 °C in a 
humidified incubator and cultured for 3 days prior to s.c. injection into C57BL/6 
mice. 
3.3.3.4 Mice 
 
Strain Background Source 
C57BL/6  C57BL/6 Harlan, Paderborn 
CX3CR1-GFP C57BL/6 Jan Hendrik Niess / University of Ulm (Niess 
et al., 2005) 
CSF2rβ KO C57BL/6 Tobias Suter / ETH Zurich (Robb et al., 1995) 
 
3.3.3.5 Equipment  
 
Device Manufacturer 
MoFlow II cell sorter Beckman Coulter 
Gallios Flow cytometer Beckman Coulter 
FACS Aria II cell sorter Becton Dickinson 
FACS Calibur Flow cytometer Becton Dickinson 
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3.2.4 Methods 
3.2.4.1 Cell culture of B16 FLT3L secreting melanoma  
B16 FLT3L secreting melanoma cells were seeded in a cell culture flask 
(75 cm2) directly after thawing in RPMI complete medium. After 2 days of 
culture at 37 °C with 5 % CO2 cells were harvested using 5 ml 
Trypsin/EDTA for 10 min at 37 °C and cells were removed subsequently 
from the tissue culture flask and centrifuged for 5 min at 1500 rpm at 4 
°C. Cells were resuspended in RPMI complete and split at a ratio of 1:15. 
After 3 days of additional growth cells were harvested using 
Trypsin/EDTA. 
3.2.4.2 Expansion of DCs by treatment with FLT3L secreting 
B16 melanoma 
B16 FLT3L secreting melanoma cells were cultured and harvested as 
described in 3.2.4.1. After harvesting, cells were centrifuged for 5 min at 
1500 rpm at 4 °C. After centrifugation cells were resuspended in PBS in 
200 µl injection volume per animal using a 1 ml insulin syringe. For 
injection animals were anesthetized with isoflurane and the injection was 
done subcutaneously (s.c.) in the neck. Mice were sacrificed 7 days after 
injection. 
3.2.4.3 Isolation of murine BM 
6-8 weeks old mice were sacrificed by CO2 asphyxia. Hind legs were 
removed from the corpus and bones were dissected in a petri dish. 
Subsequently the single femurs and tibias were opened on both sides 
and the BM was flushed out with RPMI using a 10 ml syringe with a 20 G 
needle. By pipetting up and down remaining parts of the BM were 
resuspended and the BM single cell solution was transferred into a 50 ml 
Falcon tube and centrifuged for 5 min at 1500 rpm at 4 °C. After 
centrifugation the supernatant was removed and the pellet was 
resuspended in 600 µl red blood cell lysis buffer and incubated for 5 min 
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at RT. The reaction was quenched with 20 ml of RPMI complete medium 
and centrifuged for 5 min at 1500 rpm at 4 °C. BM cells were 
resuspended in FACS or Sort buffer. 
3.2.4.4 FACS sorting of PDC subsets for adoptive transfer 
BM cells of B16 FLT3L melanoma injected mice were isolated as 
described in 3.2.4.3. Cells were resuspended in Sort buffer and 
centrifuged for 5 min at 1500 rpm at 4 °C. For antibody staining, 800 µl 
Fc receptor blocking antibody containing hybridoma supernatant was 
mixed with antibodies (antibody dilution 1:200). Cells were incubated with 
the staining solution in the dark for 15 min at 4 °C. Subsequently, cells 
were washed once with 10 ml of Sort buffer and centrifuged for 5 min at 
1500 rpm at 4 °C. Cells were then sorted using a Beckman coulter 
MoFlow cell sorter or a Becton Dickinson FACS Aria, to a purity higher 
then 95 % (For sorting strategy see Figure 4). Cells were sorted into 3 ml 
of 100 % FCS into 15 ml polystyrene tubes (Nunc, Rochester, USA). 
Quality control was done using a Beckman coulter Gallios flow cytometer 
after sorting. Data was analysed using Flow Jo flow cytometry analysis 
software (Tree star, Ashland, USA). 
3.2.4.5 Labelling of cells with Violet trace 
After FACS sorting, pDCs were centrifuged and resuspended in PBS at a 
concentration of 1 x 106 per ml and Violet trace was added at a 
concentration of 5 µM and incubated for 20 min at 37 °C in a water bath. 
The staining reaction was quenched using 10 ml of RPMI complete 
Figure 4 Sorting strategy for CCR9+ and CCR9- pDCs from BM. 
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medium and cells were incubated for 5 min at RT. Subsequently cells 
were centrifuged for 5 min at 1500 rpm at 4 °C and resuspended in 150 
µl of PBS per injection.  
3.2.4.6 Adoptive transfer of pDC subsets 
After FACS sorting and labelling of pDC subsets cells were injected 
intravenously (i.v.) in the tail veins of mice using a 1 ml insulin syringe 
(150 µl PBS injection volume) 
3.2.4.7 Isolation of cells from lymphoid tissues of mice 
Mice were sacrificed as described in 3.2.4.3 and lymphoid tissues, such 
as the mesenteric and inguinal lymph nodes as well as the spleen were 
excised. After excision, organs were minced and digested in RPMI 
containing collagenase and DNAse (concentration: collagenase 500 
µg/ml; DNAse 100 µg/ml) for 45 min at 37 °C. After incubation cells were 
passed through a 100 µm cell strainer (BD Falcon, Bedford, USA) and 
the strainer was washed twice with 10 ml of RPMI medium. Cells were 
then centrifuged for 5 min at 1500 rpm at 4 °C. After centrifugation red 
blood cell lysis was performed for 5 min as described. Lysis was stopped 
by adding 2 ml of FACS buffer and cells were then centrifuged for 5 min 
at 1500 rpm at 4 °C and resuspended in FACS buffer. 
3.2.4.8 Isolation of murine leucocytes from the lung 
Mice were sacrificed as described in 3.2.4.2. Lungs were perfused with 
ice-cold PBS, via the heart. Lungs were carefully excised and cut in 5 
mm x 5 mm size pieces and digested in RPMI containing collagenase 
(500 µg/ml) and DNAse (100 µg/ml) for 1 h at 37 °C. After digestion the 
solution was passed through a 100 µm cell strainer and the strainer was 
washed twice with 10 ml RPMI. After washing cells were centrifuged for 5 
min at 1500 rpm 4 °C. Cells were subsequently stained for FACS 
analysis as described in 3.2.4.12. 
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3.2.4.9 Isolation of murine leucocytes from the liver 
Liver was perfused with ice-cold PBS via the portal vein and cut into 5 
mm x 5 mm size pieces. Subsequently, pieces were digested for 1 h in 
RPMI containing collagenase IV (500 µg/ml) and DNAse (100 µg/ml). 
After digestion, liver pieces were passed through a 100 µm cell strainer 
and the strainer was washed two times with 10 ml of RPMI. Cell solution 
was then spun down at 1500 rpm at 4 °C for 5 min. After centrifugation, 
the pellet was resuspended in 5 ml of RPMI in a 15 ml Falcon tube and 
2.1 ml of Percoll (Sigma-aldrich, Munich, Germany) was added on top of 
the cell solution and vortexed. After vortexing the cell-Percoll solution 
was centrifuged for 15 min at 2100 rpm at room temperature without 
acceleration and deceleration. After centrifugation, the pellet contains the 
lymphocytes. The hepatocytes form a sticky layer on top of the solution, 
which is discarded. The pellet was transferred into a new tube and red 
blood cell lysis was performed. Cells were resuspended in FACS buffer. 
3.2.4.10 Isolation of murine leucocytes from blood 
Mice were sacrificed by inhalation of excess isoflurane. Directly after 
death, the chest was opened and the heart was exposed. Blood was 
drawn directly from the heart using a 1 ml 26 G Sub-Q syringe (BD, 
Franklin Lakes, USA). 50 µl of heparin solution was provided in a 15 ml 
Falcon tube in which the blood was collected. Subsequently, 10 ml of red 
blood cell lysis was added to the falcon tube and incubated for 15 min at 
RT. After incubation the solution was spun down at 1500 rpm at 4 °C for 
5 min. After centrifugation, supernatant was removed and lymphocytes 
were resuspended in FACS buffer. 
3.2.4.11 Isolation of murine leucocytes from the colon and the 
small intestine 
Mice were sacrificed as described in 3.2.4.3 and colon and / or small 
intestine were excised carefully and attached fat was removed. 
Subsequently faecal content was removed and colon and / or small 
intestine were flushed with PBS to remove additional faecal content. 
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Colon and small intestine were opened longitudinally and were cut into 3 
mm long pieces and put into ice-cold PBS and shaken vigorously. After 
shaking and settling of the tissue parts to the bottom of the Falcon tube, 
supernatant was removed and washing was performed 3 additional 
times. Tissue parts were then transferred into a 50 ml beaker tube 
containing 50 ml PBS, 2 mM DTT, 5 mM EDTA and incubated for 30 min 
at 37 °C stirring. After incubation, tissue pieces were passed through a 
100 µm cell strainer. To isolate intra-epithelial lymphocytes (IEL fraction) 
of the colon and the small intestine filtrate of the last cell straining 
process is collected in a 50 ml Falcon tube and passed through a 10 ml 
syringe filled with glass wool, up to the 3 ml mark. After glass wool 
filtration, filtrate is centrifuged for 5 min at 1500 rpm at 4 °C. After 
centrifugation the IEL fraction is resuspended in FACS buffer and can be 
analysed further. For isolation of lamina propria lymphocytes (LPL 
fraction) tissue parts remaining in the cell strainer were digested for 15 
min in RPMI containing DNAse (100 µg/ml) and collagenase (500 µg/ml) 
and shaken vigorously prior to incubation at 37 °C. After incubation tissue 
parts were passed through a 100 µm cell strainer and flow through was 
collected and centrifuged at 1500 rpm for 5 min at 4 °C. After 
centrifugation the pellet was resuspended in FACS buffer and analysed 
further. 
3.2.4.12 FACS analysis of adoptively transferred pDC subsets 
FACS staining of cells isolated as described in 3.2.4.7 - 11 was done, by 
seeding cells in 96 well u-shaped plates, followed by a centrifugation for 
5 min at 1500 rpm at 4 °C. Cells were subsequently stained using 70 µl 
Fc receptor antibody containing hybridoma supernatant mixed with 
various combinations of antibodies to mouse cell surface antigens per 
well. Cells were resuspended in the antibody FC receptor supernatant 
mixture (dilution 1:200) and incubated for 15 min at 4 °C in the dark. After 
incubation cells were washed twice using 200 µl of FACS buffer for each 
staining reaction and centrifuged for 5 min at 1500 rpm at 4 °C. After 
washing cells were resuspended in 200 µl FACS buffer and analysed 
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using a Gallios flow cytometer. Directly before analysis, 5 µl of PI 
(concentration: 50 µg/ml) was added to the cell solution for exclusion of 
dead cells. Data was analysed using Flow Jo flow cytometry analysis 
software. Gating for Violet trace+ CD11c+ cells in the PI- cell fraction 
identified transferred cells. 
3.2.3.13 Assessment of proliferation using dilution of Violet 
trace cell dye 
Proliferation of transferred cells was assessed by dilution of Violet trace 
cell dye. Cells, which proliferated showed reduction of fluorescence of 
Violet trace in comparison to unproliferated cells directly after staining 
with Violet trace. Level of Violet trace fluorescence was assessed using a 
Gallios Flow cytometer. 
3.2.3.14 Statistical analysis of results 
For statistical analysis of results shown in this thesis Student’s t-test 
(unpaired, two-tailed) was used to test for statistical significance * 
indicates p< 0.05; ** indicates p< 0.01. 
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4. Results 
4.1 Summary of results published in Blood by Schlitzer et al., 
2011 
4.1.1 CCR9- MHC class IIlow pDCs are immediate precursors of 
CCR9+ MHC class IIint pDCs 
While other lymphoid organs such as the spleen and lymph nodes only have 
very low numbers of pDCs, the BM has about 3 % pDCs in its leucocyte 
population. Accounting for 39 % ± 6.2 % of CD11c+ cells (mean ± SD, n=3). 
Within this population of BM pDCs a substantial fraction of 24.1 % ± 5.3 % (n=4) 
lack or express at a very low level the chemokine receptor CCR9 (Figure 1 A in 
Schlitzer et al., Blood, 2011). Both populations whether being CCR9+ or CCR9-
/low express critical pDC markers such as BST2, B220 and Siglec H, however 
CCR9- pDC express these at slightly lower levels. Furthermore, expression of 
MHC class II, CD80 and CD86 was lower on CCR9- pDCs compared to CCR9+ 
pDCs in the BM, showing the lower activation and less differentiated status of 
CCR9- pDCs (Figure 1 A and B, Schlitzer et al., Blood, 2011). Additionally, 
expression of CD135 (FLT3) and CD115 (MCSF-R) was similar between 
CCR9+ and CCR9- pDCs. Interestingly a small subpopulation of CCR9- pDCs 
showed a higher expression of CD115. Also mRNA expression of CSF2αr, the 
specific GM-CSF receptor chain, was similar between the two pDC subsets 
(Figure 1 B in Schlitzer et al., Blood, 2011). However CX3CR1, a chemokine 
receptor expressed on all splenic DC subsets, was also expressed on both pDC 
subsets albeit at slightly higher levels on CCR9- pDCs, as determined by mRNA 
expression as well as FACS analysis. Thus these results show that except for 
the lower expression of Sca-1 and activation associated markers such as MHC 
class II, CD80 and CD86, both populations have a characteristic pDC surface 
phenotype, concluding that this marks a close developmental relationship.  
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E2-2 was described as the critical transcription factor driving pDC development. 
We therefore determined expression of E2-2 and other DC development related 
transcription factors in CCR9- and CCR9+ pDCs sorted from the BM. E2-2 and 
IRF8 where both expressed in CCR9- pDCs albeit at slightly lower levels 
compared to CCR9+ pDCs. Spi-b, ID2 and BATF3, were also expressed in both 
populations, however no significant differences could be detected (Figure 1 B in 
Schlitzer et al., Blood, 2011). Interestingly PU.1 was significantly higher 
expressed in CCR9- pDCs than in CCR9+ pDCs. Functionally, stimulation with 
the TLR9 ligand CpG 2216 revealed differences between the CCR9- and 
CCR9+ pDC subset. CCR9- pDCs responded with higher levels of IFN-α, a pDC 
signature cytokine, to overnight stimulation with CpG 2216 compared to CCR9+ 
pDCs. Furthermore IL-6 and IL-12 was induced by CpG 2216 stimulation in 
CCR9- pDCs, whereas CCR9+ pDCs only produced very little amounts of these 
cytokines (Figure 1 D in Schlitzer et al., Blood, 2011). 
 
The rearrangement of the immunoglobulin gene locus in CCR9- and CCR9+ 
pDCs was analysed by genomic DNA PCR. As shown in Figure 1 C (Schlitzer 
et al., Blood, 2011) no rearrangement could be detected in CCR9- pDCs sorted 
from the BM, whereas CCR9+ pDCs showed DH-JH immunoglobulin gene 
rearrangement, which has been described before for a subpopulation of pDCs. 
This analysis shows that except the lack of DH-JH immunoglobulin 
rearrangement CCR9- and CCR9+ pDC share most of the characteristic pDC 
features, including the ability to produce IFN-α upon TLR stimulation. We 
therefore investigated if CCR9- pDCs can give rise to fully differentiated CCR9+ 
pDCs and incubated CCR9- and CCR9+ pDCs for 48h with or without FLT3L. 
CCR9- pDCs gave rise to fully differentiated CCR9+ MHC class II+ pDCs 48h 
after incubation with or without FLT3L, showing that CCR9- pDCs can be 
precursors of fully differentiated CCR9+ pDCs (Figure 2 in Schlitzer et al., Blood, 
2011). 
 
Additionally, CCR9- pDCs were not only found in the BM, but also in spleen, 
lymph nodes and the colon, albeit at lower numbers (supplemental figure 1 B, 
Schlitzer et al., Blood, 2011). 
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4.1.2 CCR9- MHC class IIlow pDC retain plasticity to acquire 
phenotype and function of CD11b+ MHC class IIhigh cDC-like 
cells 
It was shown recently that subsets of intestinal DCs derive from local precursors 
and that this process is shaped by the intestinal microenvironment. We 
therefore tested if the development of CCR9- pDCs can be influenced by a 
supernatant derived from intestinal epithelial cells (IEC-SN). We incubated 
CCR9- or CCR9+ pDCs sorted from the BM for 48h with 50 % of IEC-SN and 
assessed the phenotype and function of CCR9- and CCR9+ pDCs 48h after 
incubation. Exposure of CCR9- pDCs to IEC-SN leads to the downregulation of 
pDC markers such as BST2, Siglec H and B220 in a substantial fraction of 
CCR9- pDCs (35 % ± 7.4 %, mean ± SD, n=5, Figure 3 A, Schlitzer et al., 
Blood, 2011). Also lower expression of CCR9, CD8α and CD4 could be 
detected in CCR9- cultures 48h after incubation with IEC-SN compared to 
CCR9+ cultures. As shown in Fig 3 A (Schlitzer et al., Blood, 2011) exposure to 
IEC-SN for 48h lead to the generation of a CD11bhigh MHC IIhigh BST2low 
population only in cultures of CCR9- pDC but not in CCR9+ pDC cultures. This 
newly developed subpopulation of IEC-SN DCs showed high expression of 
CD11b, MHC class II as well as CD80 and CD86, thus resembling cDCs. 
Remaining BST2+ cells in these cultures retained a normal pDC phenotype and 
also upregulated CCR9, to become fully differentiated pDCs (Figure 3 A, 
Schlitzer et al., Blood, 2011). We furthermore assessed the functional 
properties of IEC-SN treated CCR9- pDC cultures. Stimulation of CCR9- pDCs 
cultured with IEC-SN and CpG 2216 results in lower secretion of IFN-α, but 
higher secretion of IL-6 and IL-12 compared to CCR9- pDCs cultured with 
medium (Figure 3 B, Schlitzer et al., Blood, 2011). We therefore hypothesized 
that BST2low cells from IEC-SN conditioned CCR9- cultures could not only have 
acquired the phenotype of cDCs but also functions of cDCs, such as efficient T 
cell activation. To test this we sorted IEC-SN DCs and IEC-SN pDCs from 48h 
conditioned CCR9- pDCs cultures and cultured both subsets, after pulsing with 
OVA protein or OVA peptide, for 4 days with OT I (CD8+) or OT II (CD4+) T cells 
respectively. As shown in figure 4 A (Schlitzer et al., Blood, 2011) IEC-SN DCs 
were significantly more efficient in inducing T cell proliferation as well as IFN-γ 
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secretion by CD4+ (OT II) T cells compared to IEC-SN pDCs. Also IEC-SN DCs 
were more efficient than splenic pDCs and CD8α- DCs in inducing OT I CD8+ T 
cell proliferation and IFN-γ production but less potent then CD8α+ DCs from the 
spleen, which are the most efficient cross-presenting DCs. (Figure 4 B, Schlitzer 
et al., Blood, 2011). Furthermore, we carefully assessed the DC compartment in 
Peyer’s patches of steady state mice and found a population of DCs which 
expresses lower levels of BST2, Siglec H and Sca-1 then BST2high pDCs but 
higher levels of MHC class II and CD11b, thereby closely resembling IEC-SN 
induced cDC-like cells derived from CCR9- pDCs (Figure 3 C, Schlitzer et al., 
Blood, 2011).  
 
These results show that CCR9- pDCs retain plasticity to divert from the pDC 
lineage under the influence of IEC-SN and are able to give rise, in addition to 
fully differentiated pDCs, to a CD11b+ MHC class IIhigh cDC-like cell subset, with 
the capacity to produce high amounts of pro-inflammatory cytokines and to 
induce robust CD4+ as well as CD8+ T cell responses. A similar cell type exists 
in the Peyer’s patches. Therefore this differentiation may also occur in vivo.  
4.1.3 Diversion of CCR9- MHC class IIlow pDCs from the pDC 
lineage is induced by GM-CSF 
Intestinal epithelial cells such as the PTK6 cell line used in this study are able to 
produce various factors, which are able to interfere with DC development. We 
were not able to detect TNF-α, IL-10, TGF-β, IL-6 or type I IFN (Fig.S4 C) in the 
IEC-SN, which have all been described to influence pDC development. GM-
CSF however, which is produced constitutively by intestinal epithelial cells and 
further upregulated upon inflammation, could be detected at low but 
reproducible levels in supernatants obtained from PTK6 monolayers (56 ± 7.5 
pg/ml, n=3). We therefore tested if pre-treatment of IEC-SN with neutralizing 
anti-GM-CSF antibody inhibited the generation of cDC-like cells (BST2low, 
CD11chigh, CD11bhigh, MHC class IIhigh cells) in CCR9- pDC cultures. After 
neutralization of GM-CSF in the IEC-SN, the generation of CD11b+ MHC class 
IIhigh cells in CCR9- pDC cultures was abrogated (Figure 5 A, Schlitzer et al., 
Blood, 2011). Also the observed enhanced production of IL-6 and IL-12 was 
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blocked by treatment of the IEC-SN with anti-GM-CSF antibody. Decreased 
production of IFN-α in IEC-SN treated CCR9- pDC cultures however was 
unaffected by neutralizing GM-CSF in the IEC-SN (Figure 5 B, Schlitzer et al., 
Blood, 2011). Vice versa addition of recombinant GM-CSF to CCR9- pDC 
cultures for 48h induced the formation of CD11b+ MHC class IIhigh cells from 
CCR9- pDC precursors (Figure 5 C, Schlitzer et al., Blood, 2011). Furthermore 
secretion of IL-6 and IL-12 was enhanced upon stimulation with CpG 2216 24h 
after conditioning with GM-CSF, however secretion of IFN-α was not inhibited 
by culture with recombinant GM-CSF suggesting that there are additional 
factors in the IEC-SN, which contribute to this effect (supplemental Figure 4 B, 
Schlitzer et al., Blood, 2011). In contrast to GM-CSF FLT3L or M-CSF added to 
CCR9- pDC cultures did not interfere with the generation CCR9+ fully 
differentiated pDCs in CCR9- pDC cultures and did not induce the generation of 
CD11b+ MHC class IIhigh cDC-like cells (Figure 5 C, Schlitzer et al., Blood, 
2011). Thus, we can conclude that GM-CSF secreted by intestinal epithelial 
cells is able to mediate deviation of CCR9- pDCs from the pDC lineage towards 
the cDC lineage and leads to the acquisition of cDC markers and enhanced 
production of proinflammatory cytokines. 
4.1.4 Diversion of CCR9- MHC class IIlow pDCs from the pDC 
lineage is marked by a profound change in the expression of 
transcription factors 
We hypothesized that the observed phenotypic and functional shift of CCR9- 
pDCs towards a cDC-like phenotype is not only transient but resembles a 
profound deviation from the pDC lineage commitment and should therefore be 
regulated on the level of transcription factors. We therefore sorted IEC-SN 
pDCs as well as IEC-SN DCs derived from CCR9- pDCs cultured with IEC-SN 
and compared expression of DC lineage specific transcription factors with 
expression in CD8α+ as well as CD8α- cDCs from the spleen by qRT-PCR 
analysis. 
 
This analysis showed that expression of E2-2 was significantly downregulated 
in IEC-SN DC as compared to IEC-SN pDCs. This was also true for E2-2 
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regulated transcripts of IRF8 and Spi-b. IRF8 levels expressed by IEC-SN DC 
were as low as levels found in CD8α- DCs but not CD8α+ DCs. Additionally, 
cDC development associated transcription factors such as ID2, BATF3 and 
PU.1 were significantly upregulated in IEC-SN DC compared to IEC-SN pDCs, 
thereby showing a cDC associated expression pattern (Figure 6, Schlitzer et al., 
Blood, 2011). 
 
These results show that upon exposure to GM-CSF containing IEC-SN CCR9- 
pDC precursors are able to deviate from the pDC lineage to the cDC lineage 
and that this developmental shift is reflected by a change in the transcription 
factor profile of the newly developed cDC-like cell. 
4.1.5 Author contributions 
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4.2 Unpublished results 
4.2.1 CCR9- and CCR9+ pDCs from the BM maintain pDC 
phenotype characteristics after in vivo expansion by FLT3L 
After identifying CCR9- pDCs in the BM as a potential precursor for CCR9+ 
pDCs and furthermore demonstrating that CCR9- pDCs are able to undergo 
lineage diversion from the pDC lineage to the cDC lineage in vitro (Schlitzer et 
al., 2011), we set out to investigate if this phenomenon can also be observed in 
vivo and if CCR9- pDCs can act as precursors to CCR9+ pDCs in vivo in the 
steady state. We therefore used an adoptive transfer model to assess the fate 
of CCR9- and CCR9+ pDCs in vivo.  
 
To obtain sufficient numbers of CCR9- and CCR9+ pDCs for transfer 
experiments DCs were expanded in vivo by subcutaneously injecting B16 
melanoma cells, which secrete high amounts of FLT3L. This syngeneic tumour 
is implanted s.c. in the neck of C57BL/6 mice and allowed to grow for 7 days. 
After expansion of DC populations we sorted CCR9- and CCR9+ pDC 
populations by the use of the pDC markers BST2 and Siglec H and the integrin 
CD11c. However to test if the expansion of pDCs by FLT3L secreting tumour 
cells changed the phenotype of pDCs in the BM or the ratio of subpopulations, 
we monitored expression of pDC signature molecules on CCR9- and CCR9+ 
pDC directly after sorting. As shown in Figure 5 CCR9+ pDCs expressed all 
pDC related markers at a high level, such as Siglec H and BST2. Furthermore 
CCR9+ pDCs show intermediate expression for CD11c and CX3CR1 and only 
low levels of CD11b, which is in accordance to the published literature and our 
previous findings (Schlitzer et al., 2011). CCR9- pDCs, depicted in Figure 5, 
expressed similar levels of the pDC specific markers Siglec H and BST2 
compared to CCR9+ pDCs. Furthermore the expression levels of CD11c, 
CD11b are very similar to those of CCR9+ pDCs. However CX3CR1 expression 
was elevated in CCR9- pDCs, similar to levels which are found in cDC 
populations in the spleen. Higher expression of CX3CR1 was also seen in the 
BM of unmanipulated mice (shown in Schlitzer et al.). 
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MHC class II can be used as a marker of pDC differentiation and maturation, 
therefore we also assessed MHC class II expression on both CCR9+ and CCR9- 
pDCs and found that CCR9+ pDCs expressed higher levels of MHC class II on 
their surface than CCR9- pDCs, hinting at a more differentiated and mature 
status of the CCR9+ pDCs. Also the level of MHC class II expression was 
slightly higher on CCR9- pDC from BM of mice bearing the FLT3L producing 
tumour then for untreated mice. 
 
Taken together this data shows that CCR9+ and CCR9- pDCs both express 
pDC specific markers, therefore are both part of the pDC lineage, but differ in 
differentiation and maturation status and the expression of CX3CR1. CCR9- 
MHCIIlow CX3CR1high pDCs are phenotypically less mature and differentiated in 
comparison to CCR9+ pDCs. Additionally FLT3L-mediated expansion does not 
greatly alter expression of pDC surface molecules in the BM of WT mice. 
 
 
 
 
 
 
 
 
 
 
Figure 5 CCR9- pDC show pDC surface marker expression, but 
immature differentiation and maturation status compared to CCR9+ 
pDCs; FACS sorted 7 day FLT3L expanded BM CCR9- and CCR9+ pDCs 
were assessed for the expression of depicted markers in steady state 
C57BL/6 mice by flow cytometry. One representative experiment shown 
(n=3). 
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4.2.2 CCR9- and CCR9+ pDCs are equally expanded by 
treatment with FLT3L 
To assess if both pDC subsets in the BM are equally responsive to FLT3L, a 
critical growth factor for DCs, we transplanted FLT3L secreting melanoma cells 
into steady state C57BL/6 mice and analysed transplanted and non-
transplanted mice 7 days later. As shown in Figure 6 A 7 day FLT3L exposure 
induced a robust 3-fold expansion of the pDC subset in the BM (FLT3L treated 
9.75 % ± 1.75 %; untreated 3.18 % ± 0.41 %; mean ± SD). Both the CCR9+ and 
CCR9- pDC subsets in the BM were expanded upon exposure to FLT3L (Figure 
5 B). CCR9+ pDCs accounted for 83.6 % ± 1.6 % (mean ± SD) in FLT3L 
exposed mice versus 85.3 % ± 3.1 % (mean ± SD) in untreated mice of the total 
pDC population in the BM. The proportion of the CCR9- pDC subset remained 
unchanged (12 % ± 3.2 % in FLT3L exposed mice; 14.7 % ± 3.2 % in untreated 
mice; mean ± SD), showing that both populations respond similarly to FLT3L. 
 
 
 
 
 
 
 
 
Figure 6 Exposure to FLT3L expands both the CCR9- and CCR9+ pDC 
populations equally; (A) Mice were exposed or not for 7 days to B16 
melanoma secreting FLT3L. Proportion of pDCs in total PI- BM leucocytes 
was monitored by flow cytometry (n=5, mean ± SD); (B) Percentage of 
CCR9- pDC within the total pDC population in the BM of day 7 FLT3L 
exposed and not exposed mice (n=5, mean ± SD). 
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4.2.3 CCR9- pDCs are present in all major lymphoid and non-
lymphoid organs 
After having found that CCR9- pDCs isolated from the BM are able to serve as 
CCR9+ pDC precursors and can also differentiate into cDC-like cells in 
response to tissue-derived factors in vitro, we determined the abundance of 
CCR9- pDC precursors in blood, lymphoid organs and non-lymphoid organs of 
steady state mice. 
Figure 7 CCR9- pDCs are present in all major lymphoid 
and non-lymphoid organs; (A) BM, SPL, LN, PP, LG, BL 
and LI were analysed by flow cytometry for the expression 
of CCR9 and CD11c in the BST2+ Siglec H+ CD11cint PI- 
population. Numbers indicate percentages within the total 
pDC population. One representative experiment out of 3 is 
shown (B) Statistical analysis of CCR9- pDC abundance in 
the pDC population in BM, SPL, LN, PP, LG, LI, BL is 
shown (n=3, mean ± SD). 
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Analysis of BM, spleen (SPL), lymph nodes (pooled mesenteric and inguinal 
lymph nodes, LN), Peyer’s patches (PP), lung (LG), blood (BL) and liver (LI) 
revealed that within the Siglec H+ BST2+ CD11cint PI- population of pDCs a 
significant fraction of CCR9- pDCs was present in all major organs and the 
blood (Figure 7 A and B). 
 
In the BM, which has approximately 3 % pDCs among its lymphocyte 
population, 16.5 % ± 3.1 % (mean ± SD) CCR9- pDCs were found in the steady 
state. In spleen, lymph node and Peyer’s patches, which harbour significantly 
smaller pDCs populations than the BM (between 0,5 % and 1 % of the total 
lymphocyte population) still between 5 % and 7 % of the pDC population were 
negative or low for CCR9. In the blood CCR9- pDCs were also observed (3.8 % 
± 2.9 %; mean ± SD) showing that CCR9- pDCs circulate within the blood 
stream and are thus able to seed lymphoid as well as non-lymphoid organs. 
CCR9- pDCs can also be identified in non-lymphoid organs such as the lung 
and liver. Interestingly the frequency of CCR9- pDCs was highest in 
hematopoietic organs – BM and liver. Showing that CCR9- pDCs are not only 
present in lymphoid organs and the blood, but are also able to enter non-
lymphoid organs and persist in these organs. 
4.2.4 CCR9- and CCR9+ pDCs display a similar chemokine 
receptor expression pattern 
To address the question if these two cell populations differ in their abilities to 
home to different sites in the body, expression of several chemokine receptors 
was measured on the surfaces of CCR9- and CCR9+ pDCs. In pDCs CCR7, 
CXCR3 and CXCR4 are indicated in the recruitment to peripheral organs and 
especially to the lymph node (Seth et al., 2011). Furthermore we investigated 
the expression of CCR6 and CCR4, which are chemokine receptors associated 
with homing of leucocytes to the gut and the lung under steady state and 
inflammatory conditions (Heiseke et al., 2011; Ito et al., 2011). As shown in 
Figure 8 CCR9- pDCs showed low but significant expression of the chemokine 
receptor CCR7. Interestingly the more mature population of CCR9+ pDCs 
displayed higher levels of CCR7 in the steady state in BM and spleen. 
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Furthermore CCR9+ pDCs in the BM and the spleen also display elevated levels 
of CCR6, a chemokine receptor associated with homing to mucosal interfaces, 
especially important in the small intestine. Additionally CCR9+ pDCs have a 
higher expression of the inflammation associated chemokine receptors CXCR3, 
CXCR4 and CCR4 in BM and spleen compared to only low levels of these 
chemokine receptors on the surface of CCR9- pDCs, as determined by flow 
cytometric analysis. Higher expression of chemokine receptors in CCR9+ pDC 
in the spleen as well as in the BM correlate with the more mature phenotype of 
the CCR9+ pDCs. 
 
As shown in Figure 8 C, CCR9- and CCR9+ pDCs in the blood of steady state 
WT mice do not differ substantially in the expression of CCR4 on their surfaces. 
Figure 8 Analysis of chemokine receptor expression on CCR9- 
and CCR9+ pDCs in BM, spleen and blood of WT mice; CCR9- 
and CCR9+ Siglec H+ BST2+ CD11cint PI- pDCs in BM, spleen and 
blood were analysed by flow cytometry for the expression of CCR7, 
CXCR3, CCR6, CXCR4 and CCR4 directly after isolation. One 
representative experiment shown out of 3. Histograms show 
antibody staining (open histograms) against unstained control (filled 
histograms). 
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However CCR4 expression on CCR9+ pDCs is higher then on CCR9- pDCs in 
the blood similar to what was found in BM and spleen. Additionally comparing 
BM, spleen and blood CCR9+ pDCs and their expression of the tested 
chemokine receptors, CCR9+ pDCs downregulate all five tested receptors once 
they enter the blood stream, whereas CCR9- pDCs upregulate CCR4 upon 
entry to the blood stream in steady state WT mice. 
4.2.5 Rapid accumulation of CCR9+ and CCR9- pDCs in 
lymphoid organs after adoptive transfer in steady state mice 
The distribution of CCR9- and CCR9+ pDCs in the organs in vivo was assessed 
by the use of an adoptive transfer system. CCR9+ or CCR9- pDCs were isolated 
Figure 9 Recovery of adoptively transferred CCR9+ and CCR9- pDCs 
12h, 24h and 48h after transfer in BM, SPL, LN and PP; (A) 12 – 48h 
kinetic of WT CCR9+ pDC recovery (Violet trace+, CD11c+, PI-) transferred 
into WT steady state recipients; (B) 12 – 48h kinetic of WT CCR9- pDC 
recovery (Violet trace+, CD11c+, PI-) transferred into WT steady state 
recipients; Recovery was assessed by flow cytometry, at the time points 
indicated. Pooled results of 4 independent experiments are shown (n=4, 
mean ± SD). 
50 
from FLT3L expanded C57BL/6 WT mice and labelled with Violet trace. After 
labelling, 5 x 105 CCR9- or CCR9+ pDC were injected i.v. into WT steady state 
recipients and detected in the BM and lymphoid organs at 12h, 24h and 48h 
post transfer. As shown in Figure 9 A CCR9+ pDCs enrich in the BM of 
recipients and reach a plateau at the 24h time point whereas in spleen, lymph 
node and Peyer’s patches appearance of CCR9+ pDC gradually increased until 
48h after injection. In contrast to that CCR9- pDCs seemed to be recruited more 
rapidly to the BM, because recovery of CCR9- pDCs after transfer was already 
maximal 12h post injection and did not increase substantially after this time 
point. In the periphery however, CCR9- pDCs increase in spleen, lymph nodes 
and Peyer’s patches until 48h after injection similar to what is seen after transfer 
of CCR9+ pDCs (Figure 9 B). These kinetics show that CCR9+ as well as CCR9- 
pDCs are rapidly recruited to the BM as well as to peripheral lymphoid tissues 
such as the spleen, lymph nodes and Peyer’s patches. However it is not clear if 
there is further increase in spleen, lymph nodes and Peyer’s patches, which is 
due to proliferation or secondary recruitment, as our analysis did not expand to 
more then 48h. Despite this, the 48h time point was chosen as a suitable time 
point for phenotypic analysis, because sufficient numbers of transferred cells 
could be recovered from all assessed organs. 
4.2.6 CCR9- and CCR9+ pDCs accumulate in all major lymphoid 
and non-lymphoid organs upon adoptive transfer 
After identifying 48h as a time point, which is suitable for analysis of transferred 
CCR9- and CCR9+ pDCs after adoptive transfer, we monitored recovery of 
Violet trace+ CD11c+ PI- pDC populations at 48h after transfer by flow 
cytometry. As shown in Figure 10 CCR9- and CCR9+ pDCs were able to home 
to the BM to the same extent 48h after transfer. Similarly also in the spleen and 
lymph node no difference in recovery of CCR9- and CCR9+ pDCs could be 
detected indicating that homing to these secondary lymphoid organs is not 
different between CCR9- and CCR9+ pDCs, which is in accordance with the 
only minimal difference in expression of CCR7 (slightly lower expression of 
CCR7 on CCR9- pDCs). However CCR9- pDCs homed significantly better to 
Peyer’s patches than CCR9+ pDCs upon adoptive transfer (Figure 10 A). This 
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data shows that CCR9- pDCs 48h after adoptive transfer home efficiently to the 
BM and secondary lymphoid organs such as the spleen and lymph nodes and 
furthermore have an advantage over CCR9+ pDCs to enter the Peyer’s patches 
 
We also assessed recovery of transferred cell populations in the blood and in 
non-lymphoid organs such as the lung, liver, small intestine and the colon 
(Figure 10 B and C). 48h after adoptive transfer donor cells could be recovered 
in all analysed organs and the blood. However, several interesting differences in 
the homing properties of CCR9- and CCR9+ pDCs to non-lymphoid organs 
could be observed. Transferred CCR9- pDCs homed significantly better to the 
lung and the colon of recipient mice, although only few cells were recovered 
Figure 10 Recovery of adoptively transferred CCR9- and CCR9+ pDCs 48h after 
transfer in lymphoid and non-lymphoid organs; (A) Recovery of transferred Violet 
trace+ CD11c+ PI- CCR9- or CCR9+ pDCs 48h after i.v. transfer in BM, SPL, LN and PP. 
(B) Recovery of transferred Violet trace+ CD11c+ PI- CCR9- or CCR9+ pDCs 48h after 
i.v. transfer in lung, SI, colon and blood. (C) Recovery of transferred Violet trace+ 
CD11c+ PI- CCR9- or CCR9+ pDCs 48h after i.v. transfer in liver. Recovery was 
assessed by flow cytometry in the indicated organs. Pooled results of 3 independent 
experiments are shown. Asterisks indicate statistical significance; p<0.05, Student’s t-
test. 
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from the colon. However, there was no difference in homing to the liver and the 
small intestine (Figure 10 B and C). Also no significant difference could be 
observed in the ability of CCR9- or CCR9+ pDCs to recirculate or to persist in 
the blood 48h after transfer, although a trend towards a higher CCR9- pDC 
recovery in the blood was detected. 
 
In conclusion CCR9- and CCR9+ pDCs can be recovered to a similar extend in 
BM, spleen, lymph nodes (mesenteric and inguinal lymph nodes, pooled), small 
intestine, liver and the blood, but differ in their ability to enter or to persist in the 
lung, in the colon and in the Peyer’s patches. 
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4.2.7 CCR9- but not CCR9+ pDCs downregulate pDC-specific 
surface molecules in lymphoid and non-lymphoid organs 
Since CCR9- pDCs were able to generate mature CCR9+ pDCs in vitro but 
could still deviate from the pDC lineage to the cDC lineage, we hypothesized 
that this could also occur in vivo. We therefore monitored expression of BST2 
and CD11c on Violet trace-labelled CCR9- and CCR9+ pDCs 48h after transfer 
in lymphoid and non-lymphoid organs. As shown in Figure 11 A, transferred 
CCR9+ pDCs largely maintained expression of BST2 48h after transfer, whether 
in the BM or in the peripheral lymphoid organs, such as the spleen, lymph 
nodes and Peyer’s patches. This was also the case in liver, small intestine and 
in the lung, although the pDC phenotype of transferred CCR9+ pDCs in the lung 
Figure 11 Percentage of BST2+ CD11c+ Violet trace+ PI- cells in lymphoid 
and non-lymphoid organs 48h after adoptive transfer of CCR9- or CCR9+ 
pDCs; (A) Percentage of BST2+ CD11c+ Violet trace+ CCR9- or CCR9+ cells 48h 
after i.v. transfer in BM, SPL, LN, PP. (B) Percentage of BST2+ CD11c+ Violet 
trace+ CCR9- or CCR9+ cells 48h after i.v. transfer in LI, LG and SI. Expression 
of BST2, CD11c and Violet trace was monitored by flow cytometry. Pooled 
results of 3 independent experiments are shown. Asterisks indicate statistical 
significance; p<0.05, Student’s t-test. 
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was less stable. In contrast, a fraction of transferred CCR9- pDCs had already 
downregulated BST2 expression 48h after transfer in spleen (64.8 % ± 1.6 % 
BST2+ cells; mean ± SD), lymph nodes (59 % ± 10.9 % BST2+ cells; mean ± 
SD) and Peyer’s patches (60.6 % ± 14.5 % BST2+ cells; mean ± SD) (Figure 11 
A) and also in non-lymphoid organs such small intestine (74.1 % ± 5.2 % BST2+ 
cells; mean ± SD) and the lung (54.5 % ± 13.4 % BST2+ cells; mean ± SD) 
(Figure 11 B). Downregulation of BST2, here used as a surrogate marker for a 
pDC specific phenotype, was significantly downregulated in spleen, lymph 
nodes and Peyer’s patches, however was maintained in the BM (90.4 % ± 6.1 
% BST2+ cells; mean ± SD) (Figure 11 A). Furthermore downregulation of BST2 
was also found in the lung and small intestine, but was maintained in the liver 
(84.1 % ± 5 % BST2+ cells; mean ± SD) (Figure 11 B). These results show that 
a substantial fraction of CCR9- pDCs downregulated BST2 48h after adoptive 
transfer deviating from the pDC lineage. This loss of pDC phenotype was found 
in peripheral lymphoid organs and non-lymphoid organs but not in BM and liver. 
At these hematopoietic and former hematopoietic sites pDC specific marker 
expression is maintained. 
 
In conclusion CCR9- pDCs retain the potential to divert from the pDC lineage. 
This event occurs in the steady state in vivo and depends on tissue specific 
factors. 
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4.2.8 CCR9- pDCs give rise to CCR9+ pDCs and to CD11b+ MHC 
class IIhigh cDCs locally in the tissues 
To further elucidate the phenotypical changes of transferred CCR9- pDCs and 
to prove the hypothesis that CCR9- pDCs can give rise to CCR9+ fully 
Figure 12 Phenotype of adoptively transferred CCR9- 
pDCs 48h after transfer; FACS sorted BM Violet trace+ 
CCR9- pDCs from FLT3L expanded donors, were transferred 
i.v. into steady state hosts and surface expression of MHC 
class II, CD11b, CCR9 and Siglec H was assessed by flow 
cytometry in SPL, BM, LN and PP 48h after transfer. Cells 
shown in dot blots and histograms were gated PI-. One 
representative experiment shown out of 3. Histograms show 
antibody staining (open histograms) against unstained control 
(filled histograms). 
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differentiated pDCs like a bona fide pDC precursor in vivo, we transferred 
sorted Violet trace-labelled CCR9- pDCs into steady state hosts and analysed 
their phenotype 48h after i.v. transfer. We analysed the surface expression of 
BST2, CD11c, MHC class II, CD11b, CCR9 and Siglec H on Violet trace+ PI- 
cells in spleen, BM, lymph nodes and Peyer’s patches by flow cytometric 
analysis. As shown in Figure 12, a fraction of Violet trace+ cells in the spleen 
showed downregulation of BST2 as well as Siglec H 48h after transfer. 
Additionally, cells which downregulated BST2 and Siglec H (SPL, R2 upper 
panel) upregulated CD11b and strongly upregulated MHC class II, in contrast to 
pre transfer levels (see Figure 5) resembling the phenotype of recipient cDCs in 
the spleen (Figure 13). A fraction of cells with a cDC-like phenotype can be 
found in all analysed tissues (R2 gate in BM, lymph nodes and Peyer’s 
patches). Cells, derived from transferred CCR9- pDCs, which maintain 
Figure 13 CCR9- pDC originated pDCs and cDCs share 
surface characteristics with the endogenous pDC and 
cDC pool; Comparison between splenic pDC and cDC to 
adoptively transferred CCR9- pDC progeny 48h after 
transfer in the spleen of steady state mice. All blots gated 
PI-. Histograms show antibody staining (open histograms) 
against unstained control (filled histograms). 
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expression of the pDC specific surface markers BST2 and Siglec H (depicted in 
the R1 gates in Figure 12) develop into mature CCR9+ pDCs characterized by a 
high expression of CCR9, intermediate MHC class II expression (higher than 
pre transfer levels) and low expression of the integrin CD11b. These results 
show that CCR9- pDCs can develop locally into phenotypically mature CCR9+ 
pDCs. CCR9- pDCs are therefore true precursors of CCR9+ pDCs. Also in 
comparison to the recipient’s pool of pDCs and CCR9+ pDCs in the spleen, 
CCR9+ pDCs originating from CCR9- pDC precursors share similar expression 
levels of Siglec H, CD11b and CCR9 with their endogenous counterparts 
(Figure 13). However, the percentages of cells which deviate from the pDC 
lineage by downregulation of pDC markers (BST2, Siglec H) and upregulation 
of CD11b and MHC class II are much higher in secondary lymphoid organs than 
in BM. Where this effect seems to take place only to a very limited extend. 
These data indicates that CCR9- pDCs retain plasticity to divert towards the 
cDC lineage in vivo in the absence of immune stimulation. 
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4.2.9 CX3CR1 is not required for CCR9+ or CCR9- pDC 
recruitment to the BM or peripheral lymphoid organs upon 
adoptive transfer 
As CX3CR1 was indicated as a critical factor for monocyte homing and is also 
critical for localization and function of DCs in the gut and the lung, we tested if 
deficiency in CX3CR1 affects the distribution of transferred CCR9+ or CCR9- 
pDCs in BM, spleen, lymph nodes or Peyer’s patches (Auffray et al., 2007; 
Jakubzick et al., 2008; Niess et al., 2005). We therefore transferred 5 x 105 
CX3CR1 deficient CCR9+ or CCR9- pDCs into steady state WT recipients and 
compared the recovery in the aforementioned organs with that of WT cells 48h 
after transfer. As shown in Figure 14 A, adoptively transferred CX3CR1-
deficient CCR9+ pDCs could be recovered to a comparable extend as WT 
CCR9+ pDCs (Same WT data shown as in Figure 10). Furthermore only small 
reductions in recovery of CCR9+ pDCs lacking CX3CR1 could be observed in 
spleen and lymph nodes, which did not reach statistical significance. Recovery 
in Peyer’s patches was not changed by the lack of CX3CR1 in CCR9+ pDCs. 
Similar to what was seen in CX3CR1 deficient CCR9+ pDCs no differences in 
BM recovery could be observed for CX3CR1-/- compared to WT CCR9- pDCs 
48h after transfer. Also no statistically significant differences could be 
discovered in the appearance of CX3CR1-/- CCR9- pDCs in spleen, lymph node 
and Peyer’s patches. Additionally we monitored expression of BST2 on 
transferred CCR9- and CCR9+ pDCs 48h after transfer. However BST2 
downregulation was not affected by CX3CR1 deficiency (data not shown). We 
therefore conclude that CX3CR1 is not required for the recruitment and 
maintenance of CCR9+ and CCR9- pDCs in BM, spleen, lymph nodes or 
Peyer’s patches.  
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Figure 14 Recovery of transferred CCR9+ and CCR9- WT or 
CX3CR1 KO pDCs 48h after adoptive transfer to WT 
recipients in BM, SPL, LN and PP; WT or CX3CR1 KO CCR9+ 
or CCR9- pDCs were FACS sorted from the BM of day 7 FLT3L 
treated animals and transferred i.v. into steady state hosts. (A) 
FACS analysis of adoptively transferred CCR9+ pDCs 48h after 
transfer. Recovery of transferred cells gated PI-. (B) FACS 
analysis of adoptively transferred CCR9- pDCs 48h after 
transfer. Recovery of transferred cells gated PI-. Pooled results 
of 2 independent experiments are shown (n=4, mean ± SD). 
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4.2.10 A role for GM-CSF in the tissue specific migration of 
CCR9- and CCR9+ pDCs 
Blocking GM-CSF prevented the differentiation of CCR9- pDCs upon 
conditioning with IEC-SN in vitro (Schlitzer et al., 2011). We therefore set out to 
study the role of GM-CSF receptor signalling on the fate of transferred CCR9- or 
CCR9+ pDCs in vivo. We therefore isolated pDCs from the BM of mice deficient 
in the common β chain of the GM-CSF receptor (CSF2rβ), which is required for 
GM-CSF, IL-3 and IL-5 signalling. CCR9- and CCR9+ pDCs were sorted from 
these mice 7 days after implantation of FLT3L-secreting melanoma. We then 
transferred 5 x 105 CSF2rβ KO CCR9- or CCR9+ pDCs into WT recipients and 
analysed the recovery in BM, spleen, lymph nodes, Peyer’s patches, lung, small 
Figure 15 Recovery of WT and CSF2rβ  deficient CCR9+ and CCR9- pDCs into WT 
steady state recipients; (A) Recovery of Violet trace+ CD11c+ PI- cells in BM, SPL, LN 
and PP 48h after transfer of WT or CSF2rβ deficient CCR9+ pDCs; (B) Recovery of Violet 
trace+ CD11c+ PI- cells in lung, SI, colon and blood 48h after transfer of WT or CSF2rβ 
deficient CCR9+ pDCs; (C) Recovery of Violet trace+ CD11c+ PI- cells in BM, SPL, LN and 
PP 48h after transfer of WT or CSF2rβ-deficient CCR9- pDCs; (D) Recovery of Violet trace+ 
CD11c+ PI- cells in lung, SI, colon and blood 48h after transfer of WT or CSF2rβ-deficient 
CCR9- pDCs; pooled results of 2 independent experiments are shown; Asterisks indicate 
statistical significance; *p<0.05, **p<0.01, Student’s t-test; (n=4, mean ± SD). 
61 
intestine, colon and blood 48h later in comparison to WT cells (WT data taken 
from experiments shown in Figure 10) CSF2rβ deficient CCR9+ pDCs could be 
recovered from the BM to a similar degree as their WT counterparts. However 
in spleen and lymph node fewer but not significantly less CSF2rβ deficient 
CCR9+ pDC were found (Figure 15 A), showing a trend towards a reduced 
appearance of CSF2rβ-/- CCR9+ pDCs in peripheral lymphoid organs. 
Furthermore significantly reduced numbers of CSF2rβ-/- CCR9+ pDCs were 
observed in the lung and small intestine in comparison to WT CCR9+ pDCs. 
Appearance of CCR9+ pDCs in the colon seemed to be independent of CSF2rβ. 
Additionally CSF2rβ deficient CCR9+ pDCs showed a trend to enrich in the 
blood compared to WT CCR9+ pDCs, however this effect did not reach 
statistical significance (Figure 15 B). In contrast to CSF2rβ deficient CCR9+ 
pDCs which appeared in similar numbers in the BM 48h after transfer, 
CSF2rβ deficient CCR9- pDCs enriched significantly in the BM of WT steady 
state recipients 48h after transfer. Also CSF2rβ deficient CCR9- pDCs showed 
no reduction in recovery in peripheral lymphoid organs (Figure 15 C). However 
in lung and small intestine a reduction in recovery of CSF2rβ-/- CCR9- pDCs 
could be observed similar to what was found in CSF2rβ-/- CCR9+ pDCs (Figure 
15 D). These results suggest that CSF2rβ plays a role for the accumulation of 
CCR9+ pDCs in peripheral lymphoid organs and is required for CCR9+ pDCs to 
accumulate in the lung and the small intestine after transfer. CCR9- pDCs 
however seem to maintain their ability to accumulate in lymphoid organs in the 
absence of signalling through the CSF2rβ but also seem to be critically 
dependent on CSF2rβ for accumulating in mucosal tissues, such as the lung 
and the small intestine. 
 
 
 
 
 
62 
4.2.11 CSF2rβ  signalling controls proliferation of CCR9- and 
CCR9+ pDCs 
Reduced recovery of transferred cells from the organs could be due to homing 
defects, reduced survival or reduced proliferation of the cells in the respective 
organs. It is know that GM-CSF is able to actively inhibit FLT3L induced gene 
programs in vivo and in vitro (Esashi et al., 2008; Gilliet et al., 2002). We 
Figure 16 Proliferation of WT or CSF2rβ  deficient CCR9- 
or CCR9+ pDCs in BM, SP, LN and PP 48h after adoptive 
transfer; (A) Proliferation of CD11c+ Violet trace+ cells in 
WT or CSF2rβ deficient CCR9+ pDC transferred WT 
recipients. (B) Proliferation of CD11c+ Violet trace+ cells in 
WT or CSF2rβ deficient CCR9- pDC transferred WT 
recipients; Proliferation was determined by dilution of Violet 
trace. Expression of BST2, CD11c and Violet trace was 
monitored by flow cytometry 48h after adoptive transfer in 
the indicated organs. Pooled results of 2 independent 
experiments are shown. Asterisks indicate statistical 
significance; *p<0.05, **p<0.01, Student’s t-test (n=4, mean 
± SD). 
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therefore investigated the effect of GM-CSF on pDC expansion and 
proliferation. Proliferation was measured by Violet trace dye dilution 48h after 
transfer of CCR9- and CCR9+ pDCs from WT or CSF2rβ-/- animals into WT 
steady state recipients. As shown in Figure 16 A CSF2rβ-/- CCR9+ pDCs 
showed significantly enhanced proliferation in BM and spleen 48h after transfer 
(BM: CSF2rβ KO: 8.5 % ± 1.2 % compared to WT: 4.3 % ± 1.7 % p< 0.05; 
spleen: CSF2rβ KO: 21.7 % ± 6.4 % compared to WT: 7.3 % ± 3.1 % p< 0.05; 
mean ± SD) and also showed a trend towards more proliferation in LN and PP 
of the same animals. Additionally, CSF2rβ-/- deficient CCR9- pDCs also 
proliferate more than WT CCR9- pDCs (Figure 16 B). In the BM up to 9.5 % ± 
0.95 % of CSF2rβ deficient CCR9- pDCs showed dilution of Violet trace 
compared to 4.6 % ± 1.4 % WT cells (p< 0.01; mean ± SD). Also in the spleen 
of these mice 13.6 % ± 2.7 % of CSF2rβ deficient CCR9- pDCs proliferated 48h 
after transfer compared to 7 % ± 2.8 % of WT cells (p< 0.01; mean ± SD). In 
conclusion these results show that CSF2rβ controls proliferation of CCR9+ and 
CCR9- pDCs in the BM and in the spleen. Enhanced proliferation of CSF2rβ-
deficient CCR9- pDCs may therefore contribute to their accumulation in the BM 
(Figure 15 C). In contrast, in the spleen increased proliferation of CSF2rβ-
deficient CCR9- and CCR9+ pDCs did not compensate for defects in migration 
and/or survival of the cells leading to similar or even reduced recovery of 
transferred cells in the spleen. 
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4.2.12 Lack of CSF2rβ  on CCR9- or CCR9+ pDCs does not 
impair the plasticity of CCR9- pDCs 
We hypothesized that GM-CSF would be required for CCR9- pDC to deviate 
from the pDC lineage, as our in vitro experiments showed that antibody 
mediated blocking of GM-CSF is sufficient to inhibit differentiation of CCR9- 
pDCs towards a cDC-like cell type after exposure to epithelial cells derived 
factors. To prove this concept in vivo we measured expression of CD11c and 
BST2 on cells derived from CCR9- and CCR9+ pDCs (WT vs. CSF2rβ KO) 48h 
after transfer in BM, spleen, lymph node and Peyer’s patches (Same 
experiments as shown in Figure 15, Figure 16 and Figure 10). As shown in 
Figure 17 A WT or CSF2rβ CCR9+ pDCs showed no or only minor 
downregulation of pDC markers such as BST2 in the BM (95 % ± 2.24 % BST2+ 
cells; mean ± SD), spleen (73.5 % ± 11.3 % BST2+ cells; mean ± SD), lymph 
nodes (83.3 % ± 12.2 % BST2+ cells; mean ± SD) and Peyer’s patches (93 % ± 
12 % BST2+ cells; mean ± SD) (Figure 17 B). Interestingly CSF2rβ deficient 
CCR9- pDCs, did not loose their ability to deviate from the pDC lineage, despite 
lack of GM-CSF signalling (Figure 17 A and C). 48h after transfer of 
CSF2rβ deficient CCR9- pDCs downregulation of pDC specific markers, such as 
BST2 was comparable to WT CCR9- pDCs in spleen (49.1 % ± 4.8 % BST2+ 
cells; mean ± SD), lymph nodes (54.7 % ± 7.3 % BST2+ cells; mean ± SD) and 
Peyer’s patches (51.9 % ± 12.6 % BST2+ cells; mean ± SD). Tissue specific 
downregulation of BST2 was maintained in CSF2rβ deficient CCR9- pDC, as in 
the BM only a minor downregulation of BST2 could be observed (88 % ± 1.4 % 
BST2+ cells; mean ± SD, Figure 17 A). Downregulation of BST2 was paralleled 
by downregulation of Siglec H and upregulation of CD11b and MHC class II, 
indicating a cDC-like phenotype as described before. These results indicate that 
in contrast to the results obtained in vitro, activity of constitutively produced GM-
CSF (via the CSF2rβ) is not critical for mediating pDC lineage diversion of 
CCR9- pDCs to cDC-like cells in vivo. Therefore it is likely that other factors are 
involved and can substitute for GM-CSF in vivo. 
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Figure 17 Percentage of BST2+ CD11c+ Violet trace+ PI- cells in BM, SPL, LN and 
PP 48h after adoptive transfer of CSF2rβ  KO CCR9- or CCR9+ pDCs; (A) Transfer 
of CSF2rβ deficient CCR9- or CCR9+ pDCs into steady state WT recipients; Expression 
of BST2, CD11c and Violet trace was monitored by flow cytometry 48h after adoptive 
transfer in the indicated organs. Pooled results of 2 independent experiments are 
shown (n=4) (B) Transfer of CCR9+ WT and CSF2rβ deficient pDCs into steady state 
WT recipients; Expression of BST2, CD11c and Violet trace was monitored by flow 
cytometry 48h after adoptive transfer in the indicated organs. Pooled results of 2 
independent experiments are shown (n=4, mean ± SD) (C) Transfer of CCR9- WT and 
CSF2rβ deficient pDCs into steady state WT recipients; Expression of BST2, CD11c 
and Violet trace was monitored by flow cytometry 48h after adoptive transfer in the 
indicated organs. Pooled results of 2 independent experiments are shown (n=4, mean 
± SD). Asterisks indicate statistical significance; *p<0.05, **p<0.01, Student’s t-test. 
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5. Discussion 
In this study we identify two distinct subpopulations in murine BM pDCs. These 
two populations, which are both highly positive for the pDC-specific surface 
molecules BST2 and Siglec H, differ in their expression of CCR9 and MHC 
class II but also have different developmental and functional properties in vitro 
and in vivo.  
 
CCR9+ pDC, which are terminally differentiated pDCs, similar to the majority of 
pDCs found in secondary lymphoid organs secrete IFN-α and low amounts of 
proinflammatory cytokines after stimulation with a TLR9 ligand. CCR9- pDCs 
secrete even higher amounts of IFN-α and higher amounts of IL-6 and IL-12. 
CCR9- pDCs express lower levels of costimulatory molecules and MHC class II 
compared to CCR9+ pDCs. On the level of transcription factors both, CCR9- and 
CCR9+ pDCs from the BM, express critical pDC related genes such as E2-2 
and Spi-b, although CCR9- pDCs express these at lower levels. CCR9+ pDCs 
are stable in their surface phenotype in vitro or after adoptive transfer in vivo. In 
contrast to that a subpopulation of CCR9- pDCs downregulated pDC markers 
and upregulated CD11b and MHC class II thus acquiring a cDC-like phenotype. 
The remaining CCR9- pDCs developed, spontaneously in vitro or after adoptive 
transfer, into fully differentiated CCR9+ pDCs, showing a developmental 
relationship between these two subsets. Additionally CCR9- pDCs are present 
in every lymphoid and non lymphoid organ and can develop independently of 
the BM environment into mature CCR9+ pDCs at these sites. Generation of 
terminally differentiated CCR9+ pDCs was regulated in a tissue specific manner, 
being more pronounced in the BM and liver than in spleen, lymph nodes, lung 
or small intestine.  
 
As a critical factor for the appearance of CCR9- pDCs and CCR9+ pDCs in lung 
and small intestine, CSF2rβ was identified. Furthermore CSF2rβ controls local 
proliferation of CCR9+ and CCR9- pDCs in BM and spleen, showing two 
unexpected roles for CSF2rβ in the control of pDC distribution and 
development. 
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5.1 CCR9- pDCs are part of the pDC lineage 
In this study we show that CCR9- pDCs and CCR9+ pDCs have a broadly 
overlapping phenotype despite the difference in CCR9 expression and the lower 
expression of MHC II, CD80 and CD86 on CCR9- pDCs. Furthermore higher 
expression of CX3CR1 and lower expression of CD4 and CD8 was detected on 
CCR9- pDCs. This shows that phenotypically CCR9- pDCs and CCR9+ pDCs 
both appear to belong to the pDC lineage. Also functionally both subsets fulfill 
the characteristics of pDCs. On the level of transcription factors both subsets 
harbour a pDC development program shown by the high expression of the 
essential pDC transcription factor E2-2 as well as IRF8 and Spi-b. However one 
major difference between CCR9- pDCs and CCR9+ pDCs remains. CCR9- 
pDCs do not harbour a rearrangement in their Ig genes as CCR9+ pDCs do. 
This corresponds to a GFP- population of pDCs identified in RAG/GFP reporter 
animals, which have a higher capacity to produce IFN-α (Pelayo et al., 2005).  
 
Furthermore CCR9 expression on pDCs isolated from the BM seemed not to be 
a requirement to enter the intestine and other mucosal associated tissue, such 
as the lung or Peyer’s patches upon adoptive transfer. Additionally in contrast to 
the published literature (Wendland et al., 2007), CCR9- pDCs were more 
efficient in homing to the Peyer’s patches and the lung and not significantly 
impaired in homing to the small intestine, hinting on the involvement of a 
different chemokine receptor for pDC homing to these peripheral tissue sites.  
 
Furthermore CCR9- pDCs can be found in all organs of the body, irrespective if 
lymphoid or non-lymphoid. This suggests that pDC development can also occur 
locally in the organs and is therefore able to adapt to the microenvironment. In 
this study treatment with FLT3L was used to expand the DC compartment in 
steady state mice, this model is widely used and has the advantage of 
expanding all DC and DC progenitor subsets allowing isolation of sufficient 
quantities of rare cell populations such as pDCs (Mach et al., 2000; Miller et al., 
2003). We compared the surface phenotypes of pDCs in untreated and FLT3L 
treated mice and did not observe differences in activation or maturation 
associated markers on pDCs. Also CCR9- and CCR9+ pDCs are expanded 
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equally, showing that this model is suitable to expand pDCs for the use in 
adoptive transfer experiments.  
5.2 Plasticity of CCR9- pDCs 
CCR9+ pDCs can be found in lymphoid organs as well as the lung, small 
intestine and liver 48h after adoptive transfer, however the phenotype of 
transferred cells is stable. CCR9- pDCs however, which can be found in 
lymphoid organs, lung, small intestine, colon and the liver show a less stable 
more plastic phenotype. Upon adoptive transfer a subpopulation of the CCR9- 
pDC-like cells have the potential to generate both pDCs - upregulating CCR9, 
MHCII, CD80 and CD86 – and cDCs downregulating pDC markers and 
upregulating CD11b and MHCII. They therefore resemble other progenitor and 
precursor populations functionally but not phenotypically.  
 
Pro-DCs or common DC progenitors (CDP, Lin- CD117int CD115+ MHC II-) were 
previously described to be able to generate pDCs and cDCs under steady state 
conditions in vitro (FLT3L BM cultures) (Naik et al., 2007; Onai et al., 2007). 
Additionally the macrophage dendritic cell progenitor (MDP, CD135+ CD115+ 
CX3CR1+) is thought to contribute towards the DC and the macrophage lineage 
(Auffray et al., 2009). Neither the MDP nor CDP express lineage markers such 
as B220 and lack CD11c expression, thereby being excluded from the CCR9- 
pDC population (BST2+ Siglec H+ B220+ CD11c+). Furthermore Pro-DCs/CDPs 
and MDPs retain the potential to proliferate extensively in vivo.  Proliferation 
was only observed for ~ 5 % of the CCR9- pDC population under steady state 
conditions, making it unlikely that one of the aforementioned progenitor 
populations contributed to the cDC lineage differentiation of 30 - 40 % of CCR9- 
pDCs. Careful phenotypic analysis also excluded the possibility that precursors 
of cDCs identified by Segura et al. contaminated the CCR9- pDC population 
causing this shift in phenotype. B220+ CD11c+ BST2- CCR9- cells from the 
spleen were indicated in a recent report to give rise to a population of cDCs in 
the spleen under steady state conditions (Segura et al., 2009). However we 
were not able to detect such a population within the CCR9- pDCs, because 
CCR9- pDCs show high expression of BST2. Additionally, contamination with 
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pre-cDCs was a possibility. Pre-cDC (Lin- CD11c+ BST2low MHCII- CD135+), 
described by Liu et al., are local precursors of cDC subsets in their various 
target organs, but are generated in the BM. A contamination by pre-cDCs could 
therefore contribute to the cDC potential of our CCR9- pDC population (Liu et 
al., 2007). However pre-cDCs are devoid of Siglec H expression and show only 
very low BST2 and B220 expression. Thus pre-cDCs are excluded by the 
sorting strategy (Figure 4, BST2+ Siglec H+ CD11cint) used in the present study. 
Additionally we also obtained gene expression profiles from CCR9- and CCR9+ 
pDCs sorted from the BM by microarray and compared these to CDP gene 
expression data from the Immgen database. This analysis showed that genes, 
which are upregulated in CDPs, are also upregulated in CCR9- pDCs but not in 
CCR9+ pDCs, providing further evidence for a progenitor cell gene expression 
signature (data not shown).  
 
Therefore CCR9- pDCs are not only immediate tissue resident precursors of 
fully differentiated CCR9+ pDCs but are also able to deviate from the pDC 
lineage under tissue specific environmental conditions. This study identifies a 
novel DC precursor that can contribute to both the pDC as well as the cDC pool.  
 
The identity of the cDC-like cells generated by CCR9- pDCs is still unclear. 
These cells resemble cDCs in phenotype and function but still maintain some 
pDC-like features, such as expression of BST2 and Siglec H at low levels, at 
least 48h after transfer. Recently, Jung et al. discovered a similar cDC-like 
population in the spleen of mice (Bar-On et al., 2010). They identified a 
population similar to our cDC-like cells. pDC related cDCs identified by Bar-On 
et al. are critically dependent on E2-2, which relates them closely to the pDC 
lineage, similar to the cDC-like cells which we observed. However certain 
differences between the two populations remain. pDC related cDCs from the 
paper by Bar-On et al. express high levels of CD8α and CX3CR1 but fail to 
cross prime T cells and lack production of IL-12p70. In contrast to that cDC-like 
cells originating from CCR9- pDC precursors produce high amounts of IL-12 
and are able to cross prime T cells upon in vitro co-cultivation, although they are 
less efficient than CD8α+ splenic cDCs (Bar-On et al., 2010). However, 
expression levels of CX3CR1 were very similar between the two cell 
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populations. Also CCR9- pDCs, which are the precursors of cDC-like cells, 
show no rearrangement in the Ig gene locus, in contrast to pDC related cDCs 
from the paper by Bar-On et al., making it unlikely that these cells arise from the 
same precursor. 
 
cDC-like cells, which are generated from CCR9- pDCs and deviate from the 
pDC lineage, not only change their phenotype, but also activate a different gene 
expression program in vitro similar to what is found in splenic cDCs. This cDC-
like gene expression program was marked by a very low expression of the 
transcription factors IRF8 and E2-2 and upregulation of BATF3 and notably ID2. 
ID2 counteracts E2-2 - the essential pDC transcription factor - by forming E2-
2/ID2 heterodimers and thereby inhibiting E2-2 functionality (Ghosh et al., 2010; 
Hacker et al., 2003). This might be one explanation for the acquisition of their 
cDC-like gene expression profile and surface phenotype. However, it is not 
entirely clear which cDC subtype cDC-like cells generated from CCR9- pDCs in 
vitro as well as in vivo resemble exactly. Low IRF8 expression is a hallmark of 
CD11b+ CD8α- DCs in the spleen and peripheral tissues (Ginhoux et al., 2009); 
therefore gene expression observed in cDC-like cells would fit this cDC 
subtype’s gene expression profile. cDC-like cells however cross-presented 
soluble antigen more efficiently than CD11b+ CD8α- splenic DCs but less 
efficiently than CD11b- CD8α+ splenic DCs in vitro. One explanation for this 
discrepancy could be that cDC-like cells generated, after 48h of incubation with 
IEC-SN or GM-CSF or post transfer from CCR9- pDC precursors are not yet 
fully developed and therefore assume an intermediate state between CD8α- and 
CD8α+ cDCs.  
 
Additionally it is not understood whether CCR9- pDCs directly develop into cDC- 
like cells or if there is a pre-cDC intermediate, which then develops into the 
various types of cDCs in peripheral tissues. This would make the CCR9- pDC an 
additional source for pre-cDCs in peripheral tissues. 
 
In vitro lineage diversion of CCR9- pDCs to cDC-like cells was critically 
dependent on the availability of GM-CSF, either recombinant or its presence in 
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the IEC-SN. It was recently observed that development of certain 
subpopulations of cDCs (CD11b+ CD103+ cDCs) especially in the lamina 
propria of the small intestine is critically dependent on GM-CSF (Bogunovic et 
al., 2009). Also GM-CSF is produced under steady state conditions at mucosal 
surfaces such as the lung and the intestine but also in the skin (Reed and 
Whitsett, 1998; Yokota et al., 2009). Furthermore GM-CSF can be induced at 
higher levels during inflammation such as colitis and citrobacter rodentium 
infection (Heiseke et al., 2011; Hirata et al., 2010). Therefore exposure of 
CCR9- pDCs to GM-CSF in peripheral non-lymphoid tissues is likely to occur in 
the resting state and even more so during inflammation. Additionally increased 
expression of PU.1 in cDC-like cells originating from CCR9- pDCs was 
detected. PU.1 is the major regulator of the expression of FLT3 and GM-CSF 
receptor further demonstrating a role for GM-CSF signalling in DC lineage 
commitment (Carotta et al., 2010). The role of GM-CSF was therefore tested in 
vivo. A knockout mouse model was used, which is deficient in the common IL-3, 
IL-5, and GM-CSF receptor chain (CSF2rβ). This model is deficient in the 
signalling of IL-5 and GM-CSF receptor but still able to signal through the IL-3 
receptor via an alternative β chain (Nishinakamura et al., 1995). After transfer of 
CSF2rβ deficient CCR9- pDCs or CCR9+ pDCs into WT recipients unexpected 
findings were obtained. Deficiency in CSF2rβ did not impair the ability of CCR9- 
pDCs to differentiate to CCR9+ fully differentiated pDCs. Also formation of the 
cDC-like cells was not inhibited, as it would have been expected according to 
the in vitro data. One explanation for this might be that IL-3 substitutes for GM-
CSF in vivo as the signalling of this closely related receptor is still intact. 
Furthermore in human DC development IL-3 and GM-CSF have similar roles in 
the establishment of lineage identity in in vitro culturing systems (Caux et al., 
1996).  
 
Also tissue specific downregulation of pDC markers and establishment of a 
cDC-like cell population from CCR9- pDCs was observed. CCR9- pDCs show 
both pDC and cDC potential but it depends on the tissue whether pDCs or 
cDCs are generated during these final differentiation steps. Cells generated 
from CCR9- pDCs in BM and liver showed only minor downregulation of BST2, 
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whereas strong downregulation was observed in secondary lymphoid organs, 
lung and small intestine. It is not clear which factors contribute to this effect, 
however M-CSF was indicated to play a major role in the final differentiation of 
pDCs in the BM, therefore this might play a role in favouring generation of 
CCR9+ pDCs from CCR9- pDCs (Fancke et al., 2008). Availability of FLT3L may 
also play a major role in these final differentiation steps (Waskow et al., 2008). 
 
In the BM, stromal cells exist which are able to build specific cell niches to 
support the differentiation process of certain cell types, such as plasma cells or 
hematopoietic stem cells (Despars et al., 2007; Tokoyoda et al., 2009). 
Therefore it is plausible that in BM and liver, hematopoietic and former 
hematopoietic organs, similar specific niches may exist which support pDC 
lineage commitment. Another interesting observation is that the lung and the 
small intestine are sites of microbial colonization and that this influences 
composition and function of the DC pool (Ng et al., 2010; Niess and Adler, 
2010), by altering the tissue microenvironment. Therefore these factors may 
have an impact on the lineage commitment of CCR9- pDCs in lung and small 
intestine but less in BM and liver. 
5.3 GM-CSF, a novel factor involved in pDC homing and 
proliferation 
CCR9- pDCs as well as CCR9+ pDCs express the specific CSF2rα chain of the 
GM-CSF receptor at a similar level and GM-CSF signalling was crucial for 
deviation of CCR9- pDCs from the pDC lineage. Despite seeing no effect on the 
generation of cDC-like cells from CSF2rβ receptor deficient CCR9- pDCs we 
could see a dramatic effect on the homing capacities of CCR9- pDCs as well as 
CCR9+ pDCs. CCR9- pDCs as well as CCR9+ pDC were not able to accumulate 
in the lung as well as in the small intestine. Furthermore CCR9- pDCs 
accumulated significantly in the BM. This can be due to maintenance, 
migration/recruitment or proliferation of pDC subsets. Recent reports showed 
that GM-CSF is necessary for the development and maintenance of several DC 
populations in the intestine as well as in the lung, including the CD103+ DCs 
and the CD11b+ CD103+ DCs (Ginhoux et al., 2009). Therefore, it is possible 
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that both pDC subsets need the GM-CSF signal to be viable in small intestine 
and lung.  
 
Figure 18 New model for DC development in the BM as well as in peripheral lymphoid 
and non-lymphoid organs. 
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Also it has been shown that GM-CSF is able to act like a chemokine. It was 
reported that GM-CSF is able to mobilize neutrophils from the microvasculature 
in a GM-CSF receptor β chain and PI3 Kinase dependent manner (Khajah et 
al., 2011). Furthermore there is evidence from a rat experimental model that 
GM-CSF also controls myocardial invasion of macrophages upon cardiac 
infarction (Kellar et al., 2011). Taken together this evidence also points to the 
role of GM-CSF as a critical factor for pDC migration and entrance to mucosal 
surfaces. 
 
We also observed an additional effect of the loss of GM-CSF receptor signalling 
in CCR9- pDCs as well as CCR9+ pDCs. Transferred CCR9- pDCs as well as 
CCR9+ pDCs lacking the GM-CSF receptor show a substantial increase in 
proliferation in BM and spleen compared to WT cells. Several different reports 
have shown that GM-CSF is able to actively suppress pDC development and 
expansion in the BM as well as in in vitro cultures (Carotta et al., 2010; Cisse et 
al., 2008; Esashi et al., 2008; Ghosh et al., 2010). Thereby it is possible that in 
the absence of GM-CSF receptor signals, FLT3L exposure in the BM and in the 
spleen leads to a re-induction of the FLT3L mediated pDC expansion. 
5.4 The origin of CCR9- pDCs 
An interesting question, which arises from these data is the origin of the CCR9- 
pDC. It is thought that mature CCR9+ pDCs arise from the CDP and from a yet 
unknown cell downstream of the lymphoid precursor (Shigematsu et al., 2004). 
Yet CCR9- pDCs do not harbour a rearrangement in their Ig genes and 
therefore most likely originate from a myeloid progenitor e.g. the CDP. 
However, it is unclear at which step of development Ig rearrangement in pDCs 
occurs and if only cells, which originate from the lymphoid precursor undergo 
the rearrangement. Therefore this is not a proof for this concept. Furthermore it 
is not clear whether CDPs can develop into CCR9+ pDCs directly without having 
to go through a pre-pDC stage such as the CCR9- pDC. Furthermore the 
question remains if only pDCs, which develop in the BM originate directly from 
the CDP or the lymphoid precursor, thereby skipping the pre-pDC stage. pDCs 
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which develop in the periphery however might originate from a local precursor, 
such as the CCR9- pDC to adapt to local tissue conditions. 
5.5 A new model for DC development 
It was thought that pDC development is exclusively happening in the BM and 
that pDCs originate directly from the CDP and a yet unknown lymphoid 
precursor cell, which harbours a Ig rearrangement, thereby limiting the capacity 
of pDCs to adapt to local tissue conditions and microenvironments. Concluding 
from the data presented here a new model for DC development is proposed 
(Figure 18): This study shows that terminally differentiated pDCs can arise from 
tissue resident precursors, such as CCR9- pDCs, directly in the peripheral 
organs thus allowing pDCs to adapt to the local microenvironment. Furthermore 
CCR9- pDC still retain plasticity to give rise to cDC-like cells, regulated by local 
tissue specific factors. This demonstrates that CCR9- pDCs are precursor cells 
which contribute to the pDC and the cDC pool and can thereby be seen as 
novel players in DC development, which are able to undergo extensive tissue 
adaptation due to their presence and development in peripheral lymphoid as 
well as non lymphoid organs. 
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6. Summary 
The data presented in this thesis identifies a subpopulation of CCR9- MHC 
class IIlow BST2+ Siglec H+ plasmacytoid dendritic cells (pDCs) within the bone 
marrow (BM) pDC population. CCR9- MHC class IIlow BST2+ Siglec H+ pDCs 
express the essential pDC transcription factor E2-2 and produce high levels of 
interferon-α (IFN-α) and proinflammatory cytokines upon toll-like receptor 9 
(TLR9) stimulation. This phenotypically immature pDC population is an 
immediate precursor for fully differentiated CCR9+ pDCs in vitro as well as in 
vivo, but does not harbour a pDC-specific gene rearrangement in the Ig gene 
locus.  
 
CCR9- pDCs retain plasticity to downregulate pDC specific surface molecules 
and upregulate CD11b and MHC class II, acquiring phenotype and function of 
CD8α- CD11b+ conventional dendritic cell (cDC) - like cells after conditioning 
with supernatant derived from colonic epithelial cells or exposure to 
recombinant granulocyte macrophage colony stimulating factor (GM-CSF) in 
vitro. Functionally cDC-like cells generated from CCR9- pDCs acquire 
properties of cDCs such as efficient T cell activation and the production of high 
levels of proinflammatory cytokines comparable to those of splenic CD8α- DCs. 
This phenotypic and functional change is also reflected on the level of 
transcription factor expression by downregulation of E2-2, Spi-b and IRF8 but 
upregulation of ID2, PU.1 and BATF3. 
 
CCR9- pDCs can give rise to fully differentiated CCR9+ pDCs and CD11b+ MHC 
class IIhigh cDC-like cells locally in the tissue in vivo in the steady state. However 
the plasticity and lineage commitment of CCR9- pDCs is regulated in a tissue 
specific manner. In BM and liver CCR9- pDCs primarily give rise to CCR9+ 
pDCs, whereas in spleen, lymph nodes, lung and small intestine a substantial 
fraction deviates from the pDC lineage to the cDC lineage.  
 
Furthermore, this study shows that GM-CSF is necessary for the appearance of 
CCR9- pDCs and CCR9+ pDCs in lung and small intestine but is dispensable for 
the generation of CD11b+ MHC class IIhigh cDCs from CCR9- pDCs in vivo. 
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Moreover, GM-CSF controls the proliferation of CCR9- and CCR9+ pDCs in BM 
and spleen upon adoptive transfer. 
 
In conclusion these results show that CCR9- pDCs are tissue resident 
precursors of pDCs and cDCs and that the generation of DC subsets is 
regulated by tissue derived factors, thereby allowing adaptation to local 
microenvironments. This increases the flexibility of the DC compartment under 
circumstances of infection or inflammation. 
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7. Zusammenfassung 
Die vorliegende Dissertation identifiziert eine Subpopulation der plasmazytoiden 
dendritischen Zellen (pDZ) im Knochenmark (KM). Diese Subpopulation 
exprimiert die pDZ spezifischen Oberflächenmoleküle BST2 und Siglec H, 
jedoch nur wenig MHC Klasse II, sowie kein oder nur wenig CCR9. Weiterhin 
exprimieren CCR9- BST2+ Siglec H+ pDZ den essentiellen pDZ 
Transkriptionsfaktor E2-2 und können außerdem nach Stimulation von TLR9 
grosse Mengen an IFN-α und geringere Mengen an inflammatorischen 
Zytokinen (IL-6 und IL-12) produzieren. CCR9- pDZ sind phänotypisch unreife 
pDZ und unmittelbare Vorläufer von voll ausdifferenzierten pDZ sowohl in vitro 
als auch in vivo, tragen allerdings keine pDZ spezifischen rearrangierten 
Immunglobulingene.  
 
Nach Inkubation mit Überstand von intestinalen Epithelzellen oder mit 
rekombinantem GM-CSF in vitro sind CCR9- pDZ in der Lage, die Expression 
der pDZ spezifischen Oberflächenmoleküle zu verringern, als auch die 
Expression von CD11b und MHC Klasse II zu erhöhen, und werden damit 
konventionellen DZ (kDZ) ähnlich. Auch funktionell zeigen diese Zellen nun 
Merkmale von kDZ. kDZ-ähnliche Zellen sind in der Lage, T-Zellen effizient zu 
aktivieren und können ebenso nach TLR9-Stimulation grosse Mengen an 
inflammatorischen Zytokinen (IL-6 und IL-12) produzieren. Des Weiteren 
spiegelt sich die Veränderung des Phänotyps und der Funktionalität auch auf 
Ebene der Genexpression wieder, da E2-2, Spi-b und IRF8 herunterreguliert 
und ID2, PU.1 und BATF3 hochreguliert werden. 
 
Nach adaptivem Zelltransfer sind CCR9- pDZ dazu in der Lage, sich sowohl zu 
voll ausdifferenzierten CCR9+ pDZ als auch zu kDZ zu entwickeln. Diese 
Plastizität ist gewebsspezifisch. Im KM und in der Leber entwickeln sich CCR9- 
pDZ hauptsächlich zu voll ausdifferenzierten pDZ, wohingegen in der Milz, den 
Lymphknoten sowie der Lunge und dem Dünndarm hauptsächlich eine 
Entwicklung zu kDZ zu beobachten ist.  
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Weiterhin zeigt diese Arbeit, dass GM-CSF nach adaptivem Zelltransfer 
ausschlaggebend dafür ist, dass CCR9- und CCR9+ pDZ sich in der Lunge und 
im Dünndarm ansammeln. Darüber hinaus reguliert GM-CSF nach adaptivem 
Zelltransfer die Proliferation von CCR9+ und CCR9- pDZ sowohl in der Milz als 
auch im KM. In vivo in Abwesenheit von Immunstimulation ist GM-CSF jedoch 
nicht der kritische Faktor, der die Generation von kDZ-ähnlichen Zellen aus 
CCR9- pDZ bewirkt. 
 
Zusammenfassend zeigen diese Ergebnisse, dass CCR9- pDZ sowohl in 
lymphoiden als auch in nicht-lymphoiden Geweben zu finden sind. CCR9- pDZ 
können dort in Abhängigkeit von lokalem Milieu entweder vermehrt in pDZ oder 
kDZ differenzieren und sich so den jeweiligen Bedingungen in den einzelnen 
Organen anpassen. Dieser Mechanismus erhöht die Flexibilität des DZ-
Kompartiments und damit die Adaption der Immunantwort bei Infektion und 
Entzündung. 
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IMMUNOBIOLOGY
Identification of CCR9! murine plasmacytoid DC precursors with plasticity to
differentiate into conventional DCs
Andreas Schlitzer,1 Jakob Loschko,1 Katrin Mair,1 Roger Vogelmann,1 Lynette Henkel,2 Henrik Einwa¨chter,1
Matthias Schiemann,2,3 Jan-Hendrik Niess,4 Wolfgang Reindl,1 and Anne Krug1
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Technical University Munich, Munich, Germany; 3Clinical Cooperation Group, Antigen-Specific Immunotherapy, Helmholtz Zentrum Munich and Technical
University Munich, Munich, Germany; and 4Department of Internal Medicine I, Ulm University, Ulm, Germany
Whereas the final differentiation of con-
ventional dendritic cells (CDCs) from com-
mitted precursors occurs locally in sec-
ondary lymphoid or peripheral tissues,
plasmacytoid dendritic cells (PDCs) are
thought to fully develop in the bone mar-
row from common DC progenitors before
migrating to the periphery. In our study,
we define, for the first time, a subpopula-
tion of CCR9! major histocompatibility
complex class IIlow PDCs in murine bone
marrow, which express E2-2 and are im-
mediate precursors of CCR9" fully differ-
entiated PDCs. However, CCR9! PDCs
have the plasticity to acquire the pheno-
type and function of CD11b" CD8#! ma-
jor histocompatibility complex class IIhigh
CDC-like cells under the influence of
soluble factors produced by intestinal
epithelial cells or recombinant GM-CSF.
This deviation from the PDC lineage com-
mitment is regulated on the level of tran-
scription factors reflected by down-
regulation of E2-2 and up-regulation of
ID2, PU.1, and BATF3. Thus, CCR9! PDCs
are immediate PDC precursors that can
be reprogrammed to differentiate into
CDC-like cells with higher antigen-
presenting and cytokine-producing ca-
pacity under the influence of the local
tissue microenvironment. (Blood. 2011;
117(24):6562-6570)
Introduction
Although plasmacytoid dendritic cells (PDCs) express markers
of the “lymphoid” lineage, they can be derived from both
common myeloid and common lymphoid progenitors.1 Several
elegant studies have convincingly shown that PDCs arise from
common dendritic cell (DC) progenitors (or pro-DCs) in the
bone marrow (BM),2,3 which have the additional potential to
generate precursor cells committed to conventional dendritic
cell (CDC) development (pre-CDCs).4,5 In contrast, common
DC progenitors derived precursor cells committed exclusively
to PDC development have not been described. Generation of
PDCs is dependent on transcription factor E2-2, which drives
the expression of other key transcription factors involved in
PDC development and function (IRF8, Spi-B, IRF7) as well as
PDC-specific markers (BST2 and Siglec H in murine PDCs,
BDCA2 in human PDCs).6
It has been reported that a population of Siglec-H-negative
PDC-like cells in murine BM, which is only present in
lymphocytic choriomeningitis virus-infected mice is capable of
differentiating into CDCs during viral infection in a type I
interferon (IFN)-dependent manner.7,8 The potential of PDCs or
committed PDC precursors to differentiate into other DC
subpopulations in the absence of infection is unknown.
It has been assumed from the available data that PDCs fully
differentiate in the BM, circulate in the blood, and then enter
lymphoid organs and peripheral tissues. CDCs, however, are
generated from circulating committed precursors (pre-CDCs),
which differentiate locally in lymphoid and peripheral tissues
under the control of growth factors, such as Fms-like tyrosine
kinase 3 ligand (Flt3L).4,9 Thus, the development of CDC
subpopulations is shaped by the local microenvironment allow-
ing adaptation to tissue-specific functions. This has been shown
recently for DCs in the intestinal lamina propria whose develop-
ment from precursors is driven by local growth factors and the
enteric microbial flora.10-12 It is so far not clear whether PDCs in
the intestine or in other peripheral tissues exclusively derive
from fully differentiated circulating PDCs13 or whether they can
also differentiate locally from committed precursor cells under
the influence of the specific tissue microenvironment.
In this study, we identify an immediate PDC precursor in
murine BM, which is characterized by expression of the
transcription factor E2-2, PDC-specific markers (BST2, Siglec
H), and production of type I IFN but lack of CCR9 and low
major histocompatibility complex (MHC) class II expression.
We show that CCR9! MHCIIlow PDCs spontaneously give rise
to fully differentiated CCR9" MHCII" PDCs. However, in
contrast to CCR9" PDCs, these cells retain the ability to divert
from the PDC lineage and differentiate into MHCIIhigh CD11b"
CD8#! antigen-presenting CDCs under the influence of GM-
CSF, which is produced constitutively by intestinal epithelial
cells. Down-regulation of the PDC-specific transcription factor
E2–2 and concomitant up-regulation of transcription factors
involved in CDC development show that this developmental
shift is transcriptionally regulated. Our results demonstrate the
existence of an immediate PDC precursor whose final differen-
tiation can be shaped by the local tissue microenvironment.
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Methods
Mice
Specific pathogen-free, female 6- to 8-week-old C57BL/6 mice were
purchased from Harlan Winkelmann. OT II and OT I mice and Cx3cr1-egfp
reporter mice (C57BL/6 background)11 were bred under specific pathogen-
free conditions. Experiments were performed in accordance with German
animal care and ethics legislation and have been approved by the local
government authorities.
Generation of Flt3-ligand generated BM-DCs
BM cells were cultured in DC medium containing 20 ng/mL recombinant
human (rh) Flt3-L for 7 days as described (FL-DCs).14
Primary cell isolation and sorting
Spleen, Peyer patches, and mesenteric and inguinal lymph nodes were
digested with collagenase D and DNase I. Single-cell suspensions from
these organs and from BM were stained with the indicated markers and
sorted using a FACSAria (BD Biosciences) or MoFlow cell sorter
(Beckman Coulter). CD4! and CD8! T cells were isolated from spleno-
cytes by negative selection using MACS technology (Milteny Biotec).
Preparation of intestinal epithelial supernatant
The murine colonic epithelial cell line PTK6 was maintained in RPMI
1640/5% fetal bovine serum/1 "g/mL insulin-transferrin-selenium/10 U/mL
rmIFN-# at 33°C as described.15 PTK6 cells were seeded on 0.5 "m pore
size transwell filters and cultured at 37°C until formation of polarized
monolayers. Monolayers were washed thoroughly with PBS and inserted
into fresh DC medium. Supernatants of intestinal epithelial cells (IEC-SN)
were harvested from the basolateral side after 24 hours, centrifuged, and
sterile-filtered before use.
DC culture and stimulation
FL-DCs and PDC subpopulations sorted from FL-DCs or primary BM cells
were cultured with 50% IEC-SN or recombinant GM-CSF or M-CSF
(concentrations indicated in figure legends) at a density of 2.5$ 106/mL for
48 hours. Cells were subsequently harvested for RNA isolation, FACS
analysis, and cell sorting. Where indicated, CpG 2216 (0.5"M, MWG
Biotech) was added after 24 hours for further 24 hours.
Antigen presentation assays
Sorted DC populations were loaded with OVA peptide (MHC class II–
specific peptide: ISQAVHAAHAEINEAGR; aa 323-339) or OVA protein
(5"M) for 1 hour and cocultured with carboxyfluorescein succinimidyl
ester (CFSE)–labeled CD4! OT II or CD8! OT I T-cells at a ratio of 1:10
for 4 days. T cells were analyzed by flow cytometry for proliferation (CFSE
dilution) and intracellular IFN-# and IL-2 after restimulation with phorbol
myristate acetate (PMA)/ionomycin.
Flow cytometry
For FACS analysis, cells were stained using fluorescently labeled antibod-
ies directed against the indicated cell surface antigens (eBioscience) as
described.14 Anti-BST2 (120G8, rat IgG1)16 and anti-Siglec H antibodies
(440c, rat IgG2b)17 were conjugated with fluorescein isothiocyanate or
biotin. XCR1 staining reagent was kindly provided by R. Kroczek.
Propidium iodide was added to exclude dead cells from analysis. T cells
were stimulated with PMA/ionomycin (20 ng/mL/1 "g/mL) for 6 hours
adding GolgiPlug and GolgiStop (BD Biosciences). Cells were then fixed in
2% paraformaldehyde, permeabilized with 0.5% saponin, and stained with
anti–IFN-#–phycoerythrin and anti–IL-2–allophycocyanin (BD Biosci-
ences). Cells were acquired using a FACSCalibur flow cytometer (BD
Biosciences) or a Gallios flow cytometer (Beckman Coulter).
Figure 1. Characterization of CCR9! and CCR9" PDCs in murine bone
marrow. Expression of the indicated markers was analyzed by FACS in primary
BM cells. Dot plots show expression of CD11c versus BST2 in propidium
iodide-negative cells and expression of BST2 versus CCR9 in BST2! CD11c!
cells. Expression of the indicated markers in CCR9! and CCR9% BST2! CD11c!
cells is shown below (overlay with fluorescence minus one [FMO] control, filled
histograms) (A). Relative mRNA expression was quantified in CCR9!/BST2!/
CD11c! and CCR9%/BST2!/CD11c! PDC populations sorted from primary BM
cells by quantitative RT-PCR (B, mean & SD, n ' 3). Immunoglobulin DH-JH
rearrangement was detected by PCR in genomic DNA isolated from CCR9! and
CCR9% PDCs (C). CCR9! and CCR9% PDCs were incubated with medium or CpG
2216 for 24 hours. IFN-(, IL-12p40, and IL-6 were measured in the supernatants
by ELISA (D, mean & SD, n ' 3). *P ) .05. **P ) .01. ***P ) .001. n.s. indicates
not significant.
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RNA isolation, cDNA preparation, and quantitative real-time
PCR
RNA was isolated using the RNeasy mini kit (QIAGEN) and transcribed to
cDNA using SuperScript III reverse transcriptase (Invitrogen). Quantitative
RT-PCR was performed using TaqMan Gene expression Master Mix
together with a TaqMan Step One Plus instrument. TaqMan probes are:
HPRT Mm00446968_m1, Tcf4 Mm01262526_g1, Sfpi1 Mm00488142_m1,
Batf3 Mm01318274, Irf8 Mm00492567_m1, Csf2ar Mm00438331_g1, Id2
Mm00711781_m1, Cx3cr1 Mm00438354, and Spib Mm01719550_s1
(Invitrogen).
Diagnostic PCR for Ig rearrangement
Genomic DNA was isolated from 5! 105 FACS-sorted cells using the
DNAeasy Blood & Tissue Kit (QIAGEN). PCR primers specific for
rearranged and nonrearranged Ig loci were used to diagnose IgH D-J
rearrangement as previously described.18
Cytokine measurement by ELISA
GM-CSF was measured by ELISA kit from eBioscience. IFN-" was
measured in supernatants by ELISA as described.14 Matched antibody pairs
and streptavidin-horseradish peroxidase (GE Healthcare) were used for
IL-6 ELISA (BD Biosciences) and IL12p40 ELISA (BD Biosciences) as
described.14
Statistical analysis
Paired, 2-tailed Student t test was used to determine statistically significant
differences.
Results
CCR9! MHCIIlow PDCs are immediate precursors of CCR9"
MHCII" PDCs
Compared with spleen and lymph nodes where the majority of
CD11c# DCs are CDCs, murine BM contains a higher percent-
age of PDCs (39% $ 6.2% of CD11c# cells, n % 3) accounting
for approximately 3% of total BM leukocytes. Among these, we
identified a fraction of 24.1% $ 5.3% (n % 4) PDCs lacking
expression or expressing very low levels of the chemokine
receptor CCR9 (Figure 1A dot plots). This population is
designated as CCR9& PDCs in this manuscript. Further charac-
terization of CCR9# and CCR9& PDCs in the BM revealed that
both populations show a phenotype characteristic for PDCs
(Figure 1A; supplemental Figure 1A, available on the Blood
Web site; see the Supplemental Materials link at the top of the
online article). In contrast to CCR9# PDCs, however, CCR9&
PDCs expressed very low levels of MHC class II and lower
levels of costimulatory molecules CD80 and CD86, demonstrat-
ing that CCR9& PDCs are less activated than CCR9# PDCs. In
addition, we observed that CD8", CD4, and Sca-1 were also
expressed at lower levels in CCR9& than CCR9# PDCs. CD115
(macrophage colony-stimulating factor receptor [M-CSFR])
was expressed at similar levels in both populations with a small
subpopulation of CD115high CCR9& PDCs. Expression of GM-
CSF receptor (csf2ar) on mRNA level was also comparable in
both populations (Figure 1B bottom right panel). CX3CR1,
which is expressed on common DC progenitors and at variable
levels on all splenic DC subpopulations, was expressed on
CCR9& as well as CCR9# BM PDCs with higher expression
levels in CCR9& PDCs (Figure 1A-B). Thus, with the exception
of very low MHC class II expression and lack of CCR9, CCR9&
PDCs phenotypically resemble CCR9# PDCs, suggesting a
close developmental relationship between these subpopulations.
The transcription factor E2-2 is critical for development of the
PDC lineage.6 We therefore determined relative mRNA expression
of E2-2 and other transcription factors involved in DC develop-
ment in sorted CCR9# and CCR9& BM PDCs (Figure 1B). E2-2
and IRF8 were expressed in both populations, albeit at slightly
lower levels in CCR9& PDCs. No significant difference was
observed in the expression of Spi-B, ID2, and BATF3, whereas
PU.1 (sfpi1) showed a higher expression in CCR9& PDCs. PCR
analysis of genomic DNA obtained from sorted CCR9& and
CCR9# PDCs revealed that only CCR9# PDCs have undergone
DH-JH immunoglobulin gene rearrangement (Figure 1C). High
level type I IFN production is a hallmark feature of PDCs, so we
stimulated BM PDCs with TLR9 ligand CpG 2216 and were able to
show that CCR9& PDCs secreted even higher amounts of IFN-"
than the CCR9# PDCs. In addition, CpG-stimulated CCR9& PDCs
produced significant amounts of IL-12 and IL-6, whereas CCR9#
PDCs produced only low levels of IL-12 (1.2$ 0.3 ng/mL;
Figure 1D).
Our analysis shows that CCR9& BM PDCs possess most of
the characteristics of CCR9# differentiated PDCs, with the
exception of CCR9 expression and DH-JH rearrangement. We
therefore investigated whether CCR9& PDCs can give rise to
CCR9# PDCs by exposing them to culture medium with or
without Flt3L for 48 hours. In both conditions, the majority of
CCR9& MHCIIlow PDCs differentiated into CCR9# MHCII#
PDCs (Figure 2). We therefore conclude that CCR9& PDCs are
precursors of CCR9# PDCs.
CCR9& PDCs are also found in spleen and lymph nodes,
although the size of this subpopulation is smaller and more variable
in these organs than in the BM (11.8%$ 6.4% of splenic PDCs,
n % 3, supplemental Figure 1C). CCR9& PDCs were also found in
mesenteric lymph nodes and in the colon. In Peyer patches,
however, CCR9 expression in PDCs was uniformly lower than in
other lymphoid organs, and a distinct population of CCR9& PDCs
could not be detected (supplemental Figure 1D). The CCR9& PDC
subpopulation in the spleen showed an almost identical phenotype
to its counterpart in the BM except for higher expression of MHC
class II (supplemental Figure 1B). Thus, CCR9& PDCs exit the BM
and could give rise to CCR9# PDCs in the periphery.
CCR9! MHCIIlow PDC precursors can differentiate to CD11b"
MHCIIhigh CDC-like cells upon exposure to intestinal epithelial
cell produced factors
It has been reported that CD11chigh DC subpopulations within the
intestinal lamina propria are generated locally from precursors
Figure 2. Differentiation of CCR9! MHCIIlow PDCs into CCR9" MHCII" PDCs.
CCR9# and CCR9& PDCs were incubated with or without Flt3-L for 48 hours.
Expression of CCR9 and MHC class II was measured by FACS. Filled histograms
represent FMO control. Results of one representative experiment are shown.
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under the influence of the tissue microenvironment. To investigate
whether differentiation of PDCs from CCR9! immediate PDC
precursors is influenced by the gut microenvironment, sorted
CCR9" and CCR9! BM PDC subpopulations were exposed to
50% IEC-SN or medium alone for 48 hours. As shown in Figure 3A
and supplemental Figure 2A, exposure of CCR9!, but not CCR9",
BM PDCs to IEC-SN led to the generation of a substantial
population of BST2low/CD11c" cells (35%# 7.4%, mean# SD,
n $ 5), which were CD11b" and expressed high levels of MHC
class II and costimulatory molecules CD80 and CD86 (IEC-SN
DC, Figure 3A histograms). The remaining BST2high PDCs in these
cultures (IEC-SN PDCs) maintained their PDC phenotype and
further up-regulated CCR9 expression (Figure 3A; supplemental
Figure 2B). Extensive phenotypic analysis of BST2low CD11c"
cells newly generated from CCR9! BM PDCs in culture with
IEC-SN (IEC-SN-DCs) showed that these cells expressed lower
levels of B220, Siglec H, CCR9, CD8%, CD4, and Sca-1, but
higher levels of MHC class II, CD80, CD86, CD11b, CD24,
CD115, CD117, and CD135 after exposure to IEC-SN than the
PDCs present in the same cultures (IEC-SN PDCs), thus resem-
bling CDCs. In contrast, CCR9" BM PDCs showed a stable PDC
phenotype even after exposure to IEC-SN (PDC" IEC-SN, supple-
mental Figure 2B). Although IEC-SN DCs expressed CD8% at low
to intermediate level, they lacked expression of XCR1, a conserved
marker of murine CD8%" splenic CDC equivalents (supplemental
Figure 2B).19 In parallel to the observed change in phenotype,
CCR9! BM PDCs cultured with IEC-SN produced significantly
less IFN-% but more IL-12 and IL-6 in response to CpG 2216
compared with cells cultured with medium alone (Figure 3B).
Phenotypic analysis of BST2" SiglecH" CD11c" cells in Peyer
patches underlying the intestinal epithelium revealed a subpopula-
tion of BST2low CD11chigh cells expressing lower levels of Siglec H
and Sca-1 as well as higher levels of MHC class II and CD11b than
BST2high CD11clow PDCs (Figure 3C). This DC subpopulation,
Figure 3. Generation of CD11b! MHCIIhigh CDC-like
cells from CCR9" MHCIIlow PDCs. CCR9" and CCR9!
PDC populations were sorted from primary BM cells,
incubated with medium or IEC-SN for 48 hours, and
stained for FACS analysis. Surface expression of BST2
versus CD11c is shown in the dot plots. Expression levels
of CD11b, MHC class II, CD80, and CD86 in BST2high
IEC-SN PDCs and BST2low IEC-SN DCs generated from
CCR9! BM PDCs after treatment with IEC-SN are shown
in the histograms (A, filled histograms: FMO control,
results of one representative of 5 experiments). CCR9"
and CCR9! PDCs were incubated with medium or 50%
IEC-SN. After 24 hours, CpG 2216 (0.5&M) was added
and cytokine concentrations were measured in the super-
natants by ELISA after further 24 hours (B, mean # SD,
n $ 3). Cells were isolated from Peyer patches digested
with DNase/collagenase and subsequently analyzed by
FACS for surface expression of the depicted markers. Dot
blots show expression of BST2 and CD11c in propidium
iodide-negative cells. Expression of the indicated mark-
ers in BST2high CD11c" (R1), BST2low CD11chigh (R2) and
CD11chigh (R3) is shown below (C, filled histograms: FMO
control). *P ' .05. **P ' .01.
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which was found in Peyer patches but not in spleen or lymph nodes,
closely resembles the CDC-like cells generated from CCR9! PDCs
in vitro under the influence of IEC-SN, with the exception of CCR9
expression, which may be influenced by local factors. Thus, the
observed deviation from the PDC lineage to a CDC-like cell type
may also occur in vivo in the intestinal microenvironment of the
Peyer patches.
CD11b! MHCIIhigh CDC-like cells generated from CCR9" PDCs
are efficient in presenting antigens to CD4! and CD8! T cells
To obtain a larger amount of CCR9! PDCs for functional studies,
we turned to CD11c" BST2" PDCs from Flt3L-cultured BM cells
(FL-DCs), which phenotypically correspond to primary CCR9!
BM PDCs and down-regulated BST2 as well as Siglec H while
up-regulating expression of CD11b, MHC class II, and CX3CR1
after exposure to IEC-SN (supplemental Figure 3A-B). The
differentiation process did not involve proliferation as shown by
lack of CFSE dilution during the 48-hour culture period (supplemen-
tal Figure 3B histograms). Therefore, with regard to both pheno-
type and function, CCR9! PDCs from FL-DC cultures are a valid
model to study the developmental fate of CCR9! BM PDCs and
the functional properties of the resultant IEC-SN DCs.
IEC-SN DCs generated from CCR9! PDCs resembled CDCs in
that they expressed high levels of MHC class II and costimulatory
molecules and produced high amounts of proinflammatory cyto-
kines. Based on these observations, we hypothesized that these
cells would be efficient T-cell activators. To compare their antigen
presentation capacity, we sorted BST2low DCs generated by treat-
ment of FL-DCs with IEC-SN (IEC-SN DCs) as well as BST2high
PDCs from medium-treated FL-DCs and cocultured them for
4 days with CD4" OT II T cells or CD8" OT I T cells after pulsing
with OVA peptide or OVA protein, respectively. IEC-SN DCs were
significantly more efficient in inducing CD4" T-cell proliferation
and IFN-# production as well as cross-presenting soluble antigen to
CD8" T cells than PDCs (Figure 4A). IEC-SN DCs were more
efficient in inducing proliferation and cytokine production of CD8"
OT I T cells than CD8$! splenic CDCs but less efficient than
CD8$" splenic CDCs (Figure 4B). Thus, CCR9!, but not CCR9",
PDCs maintain the plasticity to divert from the PDC lineage and
differentiate into CD11b" MHCIIhigh CDC-like cells with higher
capacity to produce inflammatory cytokines and present as well as
cross-present exogenous antigens upon exposure to IEC-derived
factors.
Generation of CD11b! MHCIIhigh CDC-like cells from CCR9"
PDC precursors is mediated by GM-CSF
Several soluble factors, which can be produced by IEC and could
be involved in inducing differentiation of CCR9! PDCs to CD11b"
MHCIIhigh CDC-like cells were not detectable in IEC-SN (TNF-$,
IL-10, TGF-%, IL-6, type I IFN; supplemental Figure 4C). GM-
CSF is produced at low levels in various tissues, including the
intestine in the steady state, and is further induced during inflamma-
tion and infection.20,21 Indeed, IEC-SN obtained from PTK6 cell
monolayers contained low concentrations of GM-CSF (56& 7.5 pg/
mL, n ' 3). Pretreatment of IEC-SN with neutralizing antibody
against GM-CSF largely abrogated down-regulation of BST2
(Figure 5A) and the enhanced inflammatory cytokine production in
FL-DCs exposed to IEC-SN (Figure 5B). The reduction in IFN-$
production was unaffected by blocking GM-CSF despite mainte-
nance of the PDC population (Figure 5B). Conversely, addition of
recombinant GM-CSF induced down-regulation of BST2, up-
regulation of MHC class II, and increased IL-12 and IL-6
production similar to IEC-SN (supplemental Figure 4A-B). In
contrast to IEC-SN, however, recombinant GM-CSF did not inhibit
but rather enhanced the IFN-$ response of FL-DCs to CpG 2216,
suggesting that additional IEC-derived factors are involved in
down-modulation of the IFN-$ response by IEC-SN (supplemental
Figure 4B). These results demonstrate that the differentiation of
CCR9! MHCIIlow PDCs to CD11b" MHCIIhigh CDC-like cells
Figure 4. CD4! and CD8! T-cell proliferation and
cytokine secretion in response to antigen presenta-
tion by CD11b! MHCIIhigh CDC-like cells. BST2high
PDCs and BST2low IEC-SN DCs were pulsed with OVA
peptide and cocultured with CFSE-labeled CD4! OT II
T cells or were pulsed with OVA protein and cocultured
with CD8! OT I T cells for 4 days. Proliferation was
determined by CFSE dilution, and intracellular IFN-# was
measured by FACS after stimulation with PMA/ionomycin
(A, mean & SD, n ' 3). *P ( .05. PDCs, BST2high IEC-SN
PDCs, BSTlow IEC-SN DCs, splenic CD8$" DCs, and
splenic CD8$! DCs were cocultured with OT I T cells in
the presence of OVA protein. As control, PDCs were
cocultured with OT I T cells in the absence of antigen.
After 4 days, proliferation was determined by CFSE
dilution, and intracellular IFN-# and IL-2 were detected by
FACS after restimulation with PMA/ionomycin (B, results
of 1 representative of 2 experiments are shown).
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with higher inflammatory cytokine-producing ability is mediated
by GM-CSF produced by IEC.
The observed effect of GM-CSF on the differentiation of
CCR9! PDCs was confirmed in CCR9! PDCs freshly isolated
from primary BM cells. After exposure to GM-CSF (even at very
low doses) but not Flt3L or M-CSF CCR9!, but not CCR9", PDCs
down-regulated BST2 expression (Figure 5C; supplemental Figure
4E) and up-regulated CD11b and MHC class II expression
(supplemental Figure 4D). Whereas the majority of CCR9! PDCs
further differentiated to CCR9" PDCs in the absence of growth
factors or in the presence of Flt3L or M-CSF, a substantial fraction
of CCR9! PDCs differentiated into CD11b" MHCIIhigh CDC-like
cells on exposure to IEC-SN containing GM-CSF or low concentra-
tions of recombinant GM-CSF. Thus, CCR9! immediate PDC
precursors constitute an alternative source for the generation of
CD11b" MHCIIhigh CDC-like cells under conditions where GM-
CSF is produced.
Diversion of CCR9! PDC precursors to CD11b" MHCIIhigh
CDC-like cells is regulated by transcription factors
We hypothesized that the observed differentiation of CCR9! PDCs
to CD11b" MHCIIhigh CDC-like cells is not merely a transient shift
in phenotype but rather a true diversion of lineage commitment that
should be reflected in altered expression of lineage-specific transcrip-
tion factors. We therefore sorted BST2high PDCs (IEC-SN PDCs)
and BST2low CDCs (IEC-SN DCs) generated in cultures of primary
CCR9! BM PDCs with IEC-SN as well as BST2high PDCs, which
had been cultured with medium alone. For comparison, CD8#"
and CD8#! CDCs were sorted from splenocytes. Expression levels
of transcription factors involved in PDC and CDC development
were quantified by quantitative RT-PCR.
Expression of E2-2 was greatly reduced in IEC-SN DCs
compared with the remaining IEC-SN PDCs or PDCs treated with
medium alone (Figure 6). Expression of E2-2 regulated transcrip-
tion factors IRF8 and SpiB was also reduced in IEC-SN DCs
compared with PDCs. IEC-SN DCs expressed similarly low levels
of IRF8 as CD8#! splenic CDCs distinct from CD8#" splenic
CDCs. Expression of transcription factors regulating CDC develop-
ment (ID2, BATF3, and PU.1),22-24 was greatly increased in
IEC-SN DCs compared with PDCs, thus resembling the expression
pattern found in splenic CDCs. Thus, loss of PDC-specific
phenotype and function directly correlates with down-regulation of
E2–2 and concomitant up-regulation of transcription factors in-
volved in CDC development. Upon exposure to GM-CSF–
Figure 5. Role of GM-CSF for differentiation of CCR9! PDCs
to CD11b" MHCIIhigh CDC-like cells. Neutralizing antibody
against GM-CSF (1 $g/mL) was added to IEC-SN or medium
2 hours before addition to FL-DCs for 48 hours (A-B). The
percentage of BST2high PDCs of all CD11c" cells was determined
by FACS (A, mean % SD, n & 3). CpG 2216 (0.5$M) was added
after 24 hours, and cytokines were measured in the supernatants
after further 24 hours (B, mean % SD, n & 3). *P ' .05. n.s.
indicates not significant. CCR9" and CCR9! PDCs sorted from
primary BM cells were cultured with medium alone or medium
supplemented with Flt3L (20 ng/mL), M-CSF (1 ng/mL) or GM-
CSF (1 ng/mL) for 48 hours. Expression of CD11c and BST2 was
measured by FACS. Results of one representative experiment are
shown (C).
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containing IEC-SN CCR9! immediate PDC precursors undergo a
developmental shift from the PDC lineage to the CDC lineage,
which is regulated on the level of transcription factors.
Discussion
In this study, we identify an immediate CCR9! MHCIIlow precursor
of PDCs imprinted with a PDC developmental program, which
leads to spontaneous differentiation into CCR9" MHCII" PDCs.
This population can be reprogrammed to differentiate into a
CD11b" MHCIIhigh CDC-like population upon exposure to super-
natants of IECs with low concentrations of GM-CSF as an essential
factor. This developmental shift correlates with down-regulation of
E2-2 and up-regulation of transcription factors promoting CDC
development. Thus, immediately before the final differentiation
step, exposure to GM-CSF forces CCR9! PDCs to branch off their
developmental course and contribute to the generation of CDCs.
This alternative differentiation is likely to be relevant in peripheral
tissues, such as the intestine or at sites of inflammation, where
GM-CSF is produced.
We show in our study that CCR9! MHCIIlow BM PDCs are
closely related to CCR9" MHCII" PDCs: Their phenotype largely
overlaps with the characteristic phenotype of CCR9" PDCs in BM
as well as secondary lymphoid organs with few notable exceptions:
Lack of CCR9 expression, very low expression of MHC class II,
and lower expression of CD4, CD8#, CD80, and CD86 demonstrat-
ing the lower differentiation and activation status of CCR9! versus
CCR9" PDCs. Higher levels of Sca-1 expression may reflect that
CCR9" BM PDCs are developmentally closer to splenic CCR9"
PDCs, which are Sca-1high (supplemental Figure 1). The CCR9!
BM PDC population secreted high amounts of IFN-# upon
stimulation and expressed E2-2, the essential transcription factor
driving PDC development. Thus, CCR9! BM PDCs already
possess most of the characteristic features of differentiated PDCs.
Interestingly, DH-JH immunoglobulin rearrangement was not de-
tected in CCR9! PDCs in contrast to CCR9" PDCs, yet it is
already known that expression of recombination activation gene 1
(RAG1) and subsequent DH-JH immunoglobulin rearrangement
occurs only in a fraction of PDCs ($ 50%) during later steps of
development after the common DC progenitor stage.25,26 The
Rag1!/! BM PDC population characterized by Pelayo et al25
responded to CpG stimulation with higher IFN-# and inflammatory
cytokine production, similar to our results obtained with CCR9!
BM PDCs.
CCR9! MHCIIlow PDCs are immediate PDC precursors that
retain the ability to divert from commitment to the PDC lineage and
differentiate into CD11b" MHCIIhigh CDC-like cells in the pres-
ence of IEC-SN or GM-CSF. This population, however, is distinct
from previously described common DC progenitors or pro-DCs
(Lin! c-kitint Flt3" M-CSFR") because of expression of lineage
markers B220, CD11c, CD4, CD8#, and CD86, heterogeneous
expression of M-CSFR (CD115), and lack of proliferation and
CDC differentiation in response to Flt3L.2,3 CCR9! MHCIIlow PDC
precursors may be contained within CD11c" Ly6C" CD31" B220"
“preimmunocytes” or CD11c" MHCII! B220" precursors in the
BM.27,28 In contrast to these studies, which were performed before
the identification of PDC-specific markers, we clearly show that
CCR9! MHClow PDC precursors are a well-defined mostly homo-
geneous population, which is far advanced in their differentiation
to CCR9" MHCII" PDCs and committed to PDCs under steady-
state conditions (culture with medium or Flt3L). Because of the
expression of the PDC-specific markers BST2 and Siglec H, this
population does not overlap with the CD11c" B220" BST2!
CCR9! DCs in the spleen, which give rise to splenic CDC
subsets.29
Despite their close relationship to finally differentiated CCR9"
PDCs, the CCR9! MHCIIlow PDC precursors identified in our
study retain the potential to significantly contribute to the genera-
tion of CD11b" MHCIIhigh CDC-like cells under conditions where
GM-CSF is produced. Outside of the BM, CCR9! PDC precursors,
which have the same phenotype as their BM counterparts but
express MHC class II at higher levels, were also found in spleen
and lymph nodes, suggesting that these immediate PDC precursors
leave the BM. In CCR9-deficient mice, the PDC population is
greatly diminished in the small intestine but only partially in Peyer
patches13 and not reduced in the colon.30 Therefore, PDC precur-
sors may reach Peyer patches and colonic lamina propria despite
the lack of or low expression of CCR9. We found a subpopulation
of BST2low CD11chigh cells in Peyer patches, which phenotypically
closely resembles the CDC-like cells generated from CCR9! PDCs
in vitro. The PDC-specific marker Siglec H was still expressed on
this subpopulation, although at lower levels than in PDCs, suggest-
ing a close developmental relationship to PDCs. Thus, differentia-
tion of immediate PDC precursors into CDC-like cells may also
occur in vivo at this site. The final differentiation of PDC
precursors to either CCR9" PDCs or CD11b" MHCIIhigh CDC-like
cells is therefore subjected to conditions of the local tissue
microenvironment, such as the intestine, allowing adaptation to
local requirements in the steady state as well as during inflamma-
tion or infection.
Careful phenotypic analysis of the MHCIIhigh CDC-like cells,
which were generated from CCR9! PDC precursors under the
influence of GM-CSF containing IEC-SN (supplemental Figures 2,
3), revealed that these cells expressed CD11b and CX3CR1, low
levels of CD8# and CD4, but lacked significant XCR1 and CD103
expression, markers of spleen CD8#" DC equivalents.19 This
phenotype therefore resembles that of CD8#! CD11b" splenic
CDCs or related DCs in peripheral tissues.
Very low IRF8 expression combined with increased expression
of BATF3, ID2, and PU.1 is also congruent with this phenotype.
The CD11b" MHCIIhigh CDC-like cells, which were generated
from CCR9! PDC precursors might also be related to the
Figure 6. Transcription factor expression pattern in CD11b! MHCIIhigh CDC-like
cells generated from CCR9" PDCs. CCR9" and CCR9! PDCs sorted from primary
BM cells were incubated with medium alone or 50% IEC-SN for 48 hours. Relative
mRNA expression of transcription factors was measured by quantitative RT-PCR in
sorted BST2low IEC-SN DCs and BST2high IEC-SN PDCs generated from CCR9!
PDCs cultured with IEC-SN as well as in sorted BST2high PDCs generated from
CCR9" PDCs cultured with medium alone. The expression patterns of transcription
factors in splenic CD8#" and CD8#! DCs are shown for comparison. Results of one
representative of 2 experiments are shown.
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CX3CR1! CD8"! DC population recently identified in the spleen
whose gene expression profile partially overlaps with that of
PDCs.31 Functional analysis showed that the CD11b! MHCIIhigh
CDC-like cells generated from CCR9# PDC precursors produce
higher levels of inflammatory cytokines and present exogenous
antigens to CD4! T cells and CD8! T cells more efficiently than
PDCs. The cross-presenting capacity of this CDC-like population
generated from CCR9# PDCs in vitro was higher than that of
splenic CD8"# CDCs, but lower than that of splenic CD8"!
CDCs. We conclude from these functional data that diversion from
the PDC commitment at this late stage in development allows the
generation of CDC-like cells with higher potential for efficient
induction of adaptive immune responses, which may be beneficial
in specific organs or during infections.
We found that GM-CSF is the major factor produced by IEC,
which was responsible for the observed differentiation of CCR9#
PDC precursors to CD11b! MHCIIhigh CDC-like cells in response
to IEC-SN. Type I IFN, which has been shown to drive the
generation of BST2! Siglec H# PDC-like cells in the BM, which
convert to CDCs during lymphocytic choriomeningitis virus infec-
tion, was not produced by IEC and could thus be excluded as a
relevant factor.7,8 GM-CSF is not detectable in the serum in the
steady state but increases during inflammation.20 It has been
assumed that GM-CSF is dispensable for DC development in the
steady state but influences DC differentiation during inflammation
by inducing the generation of “inflammatory” DCs from precur-
sors. However, it has been shown recently that GM-CSF controls
the development of subpopulations of lamina propria CDCs and
dermal DCs from precursor cells.10,12,32 Thus, the observed differen-
tiation of CCR9# PDC precursors to CDCs could contribute to the
generation of CDCs in peripheral tissues in the steady state.
However, GM-CSF is strongly induced and critical for host defense
during intestinal infection with the mouse enteric pathogen Citro-
bacter rodentium.21 GM-CSF is also induced and plays an essential
role in autoimmune inflammatory diseases, such as experimental
autoimmune encephalomyelitis, collagen-induced arthritis, and
myocarditis.20,33 Thus, differentiation of CCR9# PDC precursors to
CDC-like cells is probably relevant during infection and inflamma-
tion, when GM-CSF expression is induced.
E2-2 is the critical transcription factor for PDC development
and lineage stability.6 CCR9# PDCs differentiating to CD11b!
MHCIIhigh CDC-like cells in the presence of IEC-SN down-
regulate expression of E2-2 and E2-2–regulated Spi-B and IRF8,
whereas CCR9! PDCs maintain their high level expression of
E2-2. DC development is regulated by transcription factors in a
dose-dependent manner,6,22 and differentiation to DC subpopula-
tions appears to depend on the ratio of the different transcription
factors. ID2-mediated inhibition of E protein activity by formation
of inactive ID2/E2-2 heterodimers prevents PDC development34
and allows the generation of CDCs.35 Thus, down-regulation of
E2-2 and up-regulation of ID2 in CCR9# PDCs exposed to IEC-SN
is expected to prevent the activation of E2-2 target genes required
for full differentiation and stability of PDCs. The decrease in the
E2-2/ID2 ratio found in CCR9# PDCs on treatment with IEC-SN
therefore provides a good explanation for the observed diversion
from the PDC lineage commitment and differentiation into CDC-
like cells. PU.1 dose-dependently regulates DC development by
inducing and maintaining Flt3 and GM-CSF–receptor expression,
which is more critical for CDC than for PDC development.
Divergence of the CDC and PDC lineages was shown to be
paralleled by high versus low PU.1 expression.22 This is confirmed
in our study also for the reprogramming of PDC precursors to
CDC-like cells.
In conclusion, we identify CCR9# PDCs, which are found in
BM and secondary lymphoid organs as immediate PDC precursors
whose final differentiation can be shaped by the local tissue
microenvironment. In the presence of GM-CSF, which is produced
constitutively in peripheral tissues or is induced at sites of
inflammation, these immediate PDC precursors undergo profound
changes in transcription factor expression pattern leading to a
developmental shift toward CD11b! MHCIIhigh CDC-like cells
with higher cytokine-producing and antigen-presenting capacity.
This plasticity at a late stage in the PDC developmental pathway
may promote inflammation but may also be beneficial for immune
defense against pathogens.
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Fig. S1 Phenotypic characterization of CCR9+ and CCR9- PDCs in BM and 
spleen 
Expression of the indicated cell surface molecules was analysed by FACS in CCR9+ 
and CCR9- BST2+ CD11c+ BM PDCs (A) and splenic PDCs (B). Percentage of 
CCR9- BST2+ CD11c+ PDCs in BM, Spleen and mesenteric lymph node (C, mean ± 
SD, n=3). FACS analysis of CCR9 expression in BST2+CD11c+ PI-negative cells in 
inguinal and mesenteric lymph nodes as well as Peyer’s patches (D). 
 
Fig. S2 Characterization of CD11b+ MHCIIhigh CDCs generated from CCR9- BM 
PDCs upon exposure to IEC-SN 
The percentage of BST2low CD11c+ cells generated from CCR9+ and CCR9- BM PDC 
after 48 hrs culture with medium or IEC-SN versus before culture is shown (A, mean 
± SD, n=5). CCR9+ and CCR9- PDCs were sorted from primary BM cells and cultured 
with 50 % IEC-SN for 48 hrs.  Expression of the indicated cell surface molecules was 
analysed by FACS in BST2high PDCs present in the cultures of CCR9+ PDCs with 
IEC-SN (PDCs + IEC-SN, upper row) as well as in BST2high PDCs (IEC-SN PDCs, 
middle row) and BST2low DCs (IEC-SN DCs, lower row) generated in cultures of 
CCR9- PDCs with IEC-SN (B). 
 
Fig. S3 Phenotypic changes in PDCs derived from FL-DC cultures in response 
to IEC-SN 
BST2high CD11c+ PDCs were sorted from day 7 FL-DC cultures and incubated with 
medium alone or 50 % IEC-SN for 48 hrs. Expression of the indicated markers before 
incubation and after exposure to medium or IEC-SN was measured by FACS. 
Results of one representative of 4 experiments are shown (A). Day 7 FL-DCs were 
generated from BM cells of CX3CR1-eGFP reporter mice and were incubated with 
medium alone or 50 % IEC-SN for 48 hrs. Expression of CX3CR1 (eGFP) and BST2 
was analysed by FACS (B, dot plots). Day 7 FL-DCs were labeled with CFSE and 
cultured with medium alone or 50 % IEC-SN for 48 hrs. CFSE staining was analysed 
by FACS to detect proliferation. 
 
Fig. S4 Effect of recombinant GMCSF on phenotype and cytokine response of 
FL-DCs  
FL-DCs were incubated with medium alone or medium supplemented with 1 ng/ml 
GMCSF for 48 hrs (A, B). Expression of CD11c, BST2 and MHC class II was 
determined by FACS (A). CpG 2216 (0.5 µM) was added after 24 h and cytokine 
were measured in the supernatants by ELISA after further 24 h of stimulation (B, 
mean ± SD, n=3). Cytokine concentration in the IEC-SN was measured by ELISA. 
For positive controls respective recombinant cytokines were used (C, one of two 
representative experiments shown). CCR9- PDCs sorted from primary BM cells were 
cultured with medium alone or medium supplemented with GMCSF (1 ng/ml) for 48 
h. Expression of CD11b and MHC class II was measured by FACS. Results of one 
representative experiment are shown (D). CCR9- PDCs sorted from primary BM cells 
were cultured with medium alone or medium containing the indicated concentrations 
of recombinant GMCSF (range: 0.01 ng / ml – 10 ng / ml) for 48h. Expression of 
BST2 and CD11c was measured by FACS. Results of one representative experiment 
are shown (E). 
 
